NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
i
 DCP Protocol #: NWU2014-03-01   
 
Local Protocol #: NCI 2014-03-01 
 
      
Phase I trial of Berberine in subjects with ulcerative colitis 
  
 
Sponsor:     Division of Cancer Prevention, National Cancer Institute, National Institutes of 
Health 
 
Consortium Name *:   N orthwestern University , Northwestern Cancer Prevention Consortium   
Name of Consortium Principal   Seema A. Khan, MD 
Investigator:    303 E. Superior, Suite 4-111 
     Chicago, IL 60611 
Phone: 312-503-4236 
Fax:
 312-503-2555 
Email: skhan@nm.org  
 
Organization Name* :   Northwestern University, Northwestern Cancer Prevention Consortium 
Consortium Co-Principal  Lifang Hou, MD, PhD 
Investigator:    680 N Lake Shore Drive, Suite 1400 
     Chicago, IL 60611 
     Phone: (312) 503-4798 
     Fax: (312) 908-9588 
     Email: l-hou@northwestern.edu  
 
Organization Name:   Xijing Hospital of the Fourth Military Medical University (FMMU) 
Principal Investigator:   Kaichun Wu, MD, PhD 
     127 West Changle Road  
     Dept of Gastroenterology 
     Xijing Hospital  
     Xi'an 710032 
     China 
     Phone: 862984771502 
     Fax: 862982539041 
 
    E-mail: kaicwu@fmmu.edu.cn  
 
Organization Name*:   Oregon Health & Science University 
Prot
ocol Chair:    Raymond C. Bergan, MD 
     3181 SW Sam Jackson Park Road, L586 
     Portland, Oregon 97239 
     Phone: 503 348-0742 
     Fax: 503-494-4285 
  
   Email: bergan@ohsu.edu  
 
 
 
*No participant accrual occurs at this site 
  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
ii
 Or
ganization:    Xijing Hospital (FMMU) 
Investigator:    Li Xu, MD, PhD 
     127 West Changle Road 
     Dept of Gastroenterology 
     Xijing Hospital  
     Xi'an 710032 
     China 
     Phone: 862984771502 
     Fax: 862982539041 
     E-mail: lxuhelen@163.com 
 
Organization:     Xijing Hospital (FMMU) 
Investigator:    Aidong Wen, PhD 
     Director of Phase I Clinical Trials Center 
     127 West Changle Road 
     Phase I Clinical Trials Center 
     Xijing Hospital  
     Xi'an 710032 
     China 
     Phone: 862984775471 
     Fax: 86292539041 
     E-mail: adwen@fmmu.edu.cn 
 
Organization:    Xijing Hospital (FMMU) 
Investigator:    Zengshan Li, MD, PhD 
     Pathology 
     127 West Changle Road 
     Dept of Gastroenterology 
     Xijing Hospital  
     Xi'an 710032 
     China 
     Phone: 8615091596178 
     Fax: 862982539041 
     E-mail: lizsh72@fmmu.edu.cn 
 
Organization*:    Northwestern University – Feinberg School of Medicine 
In
vestigator:    Guangyu Yang, MD, PhD 
     Pathology and Toxicology 
  Department of Pathology 
  Ward 6-116  
     303 E. Chicago Avenue    
    Chicago, IL   60611  
  
Phone: (312) 503-0645  
  Fax: (312) 503-0647    
  Email: g-yang@northwestern.edu 
 
Organization*:    Northwestern University 
Stat
istician:    Borko Jovanovic, PhD 
     680 N. lake Shore Dr., Suite 1102 
     Chicago, IL 60611 
     Telephone: (312) 503-2008 
     Fax: (312) 908-9588 
     Email: borko@northwestern.edu  
 
*No participant accrual occurs at this site 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
iii
 Ag
ent(s)/Supplier:   Berberine/Shanghai Sine Tianping Pharmaceuticals 
NCI Contract #    HHSN261201200035I 
Protocol Version Date:   November 29, 2016 
 
Protocol Revision or 
Amendment #    Version 5.7 
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
iv SC
HEMA  
 
 
 
Patients 18 -70 year s old with ulcerative colitis  
in clinical remission while receiving maintenance therapy with Mesalamine  
(Ulcerative colitis disease activity index (UCDAI) ≤ 1 for ≥ 3 months)  
Baseline Data  
1. Colorectal biopsy tissue collection from 
normal and inflammatory loci  
2. Blood sample collection  
Randomization 3:1 † 
Berberine  
300 mg TID  
(12) 
Related Grade 1 *AE 
or less  
Endpoints  
1.Colorectal biopsy tissue collection from normal and 
inflammatory loci to access inflammation and anti-cancer 
markers (TNF α, COX -2, and NF -κB, Ki67, activated 
caspase -3 and DNA methylation on SFRP1, TCERGIL 
FBN2, TFP12)  
2. Blood sample collection analyzed for markers of inflammation 
(CRP, ESR, and inflammation-related cytokines by ELISA), blood 
count and blood chemistry to evaluate organ function, and Berberine 
levels in the blood (by HPLC/MS)  
Phase I trial of Berberine in subjects with ulcerative colitis  
Decrease by 100 
mg per dose  
Remove patient  
from the study  
Placebo  
(4) 
Treatment for 3 months  
Related Grade 2 
*AE 
Related Grade 3 or 
4 *AE  
Not Tolerating  
300 mg/day  
Tolerating  
≥ 300 mg/day  
†Sixteen  subjects will be randomized. Two additional subjects are anticipated to be accrued (for a total of 18 subjects) to 
account fo r anticipated dro pouts. Dropouts in either treatment group will be replaced by subjects assigned to that same 
treatment and gender group.  
* = Adverse Event  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
v
 TABLE OF CONTENTS 
 
SCHEMA ..................................................................................................................................................... iv 
TABLE OF CONTENTS .............................................................................................................................. v 
1. OBJECTIVES .................................................................................................................................. 1 
1.
1 Primary Objective ............................................................................................................................................1  
1.2 Secondary Objectives ......................................................................................................................................1  
2. BACKGROUND ............................................................................................................................. 1 
2.1 Study Disease .................................................................................................................................................. 1 
2.2 Study Agent ..................................................................................................................................................... 2 
2.3 Rationale .......................................................................................................................................................... 3 
Primary Objective: ..................................................................................................................................................... 4 
Secondary Objectives: ...............................................................................................................................................4  
3. SUMMARY OF STUDY PLAN ..................................................................................................... 6 
4. PA
RTICIPANT SELECTION ......................................................................................................... 7 
4.
1 Inclusion Criteria .............................................................................................................................................7  
4.2 Exclusion Criteria ............................................................................................................................................7  
4.3 Inclusion of Women and Minorities ................................................................................................................ 8 
4.4 Recruitment and Retention Plan ...................................................................................................................... 8 
5. AGENT ADMINISTRATION ........................................................................................................ 9 
5.1 Dose Regimen and Dose Groups ..................................................................................................................... 9 
5.2 Berberine  Administration ................................................................................................................................ 9 
5.3 Run-in Procedures ...........................................................................................................................................9  
5.4 Contraindications .............................................................................................................................................9  
5.5 Concomitant Medications ................................................................................................................................ 9 
5.6 Dose Modification ...........................................................................................................................................9  
5.7 Adherence/Compliance ................................................................................................................................ . 10 
6. PHARMACEUTICAL INFORMATION ...................................................................................... 10 
6.1 Study Agent ...................................................................................................................................................  10 
6.2 Reported Adverse Events and Potential Risks ...............................................................................................  10 
6.3  Availability ....................................................................................................................................................  10 
6.4 Agent Distribution ......................................................................................................................................... 10 
6.5  Agent Accountability ..................................................................................................................................... 11 
6.6 Packaging and Labeling ................................................................................................................................ . 11 
6.7 Storage ...........................................................................................................................................................  11 
6.8 Registration/Randomization ..........................................................................................................................  11 
6.9 Blinding and Unblinding Methods ................................................................................................................  12 
6.10 Agent Destruction/Disposal ...........................................................................................................................  12 
7. CLINICAL EVALUATIONS AND PROCEDURES ................................................................... 12 
7.1 Schedule of Events ........................................................................................................................................ 12 
7.2 Baseline Testing/Prestudy Evaluation ........................................................................................................... 13 
7.3 Evaluation During Study Intervention ........................................................................................................... 13 
7.4 Evaluation at Completion of Study Intervention ...........................................................................................  14 
7.5 Post-intervention Follow-up Period ...............................................................................................................  14 
7.6 Methods for Clinical Procedures ...................................................................................................................  15 
8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION ........................................... 15 
8.
1 Primary Endpoint ........................................................................................................................................... 15 
8.2 Secondary Endpoints ..................................................................................................................................... 15 
8.3 Off-Agent Criteria ......................................................................................................................................... 16 
8.4 Off-Study Criteria .......................................................................................................................................... 16 
8.5 Study Termination ......................................................................................................................................... 16 
9. CORRELATIVE/SPECIAL STUDIES ......................................................................................... 16 
9.
1 Rationale for Methodology Selection ............................................................................................................ 16 
9.2 Comparable Methods ..................................................................................................................................... 17 
10. SPECIMEN MANAGEMENT ...................................................................................................... 17 
1
0.1 Laboratories ...................................................................................................................................................  17 
10.2 Collection and Handling Procedures ............................................................................................................. 18 
10.3 Shipping Instructions ..................................................................................................................................... 20 
10.4 Tissue Banking ..............................................................................................................................................  21 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
vi 11.
 REPORTING ADVERSE EVENTS ............................................................................................. 21 
11.1 Adverse Events ..............................................................................................................................................  21 
11.2 Serious Adverse Events ................................................................................................................................ . 23 
12. STUDY MONITORING ............................................................................................................... 24 
12.1 Data Management .......................................................................................................................................... 24 
12.2 Case Report Forms ........................................................................................................................................ 24 
12.3 Source Documents ......................................................................................................................................... 24 
12.4 Data and Safety Monitoring Plan ..................................................................................................................  24 
12.5 Sponsor or China Food and Drug Administration Monitoring ...................................................................... 24 
12.6 Record Retention ........................................................................................................................................... 24 
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA) ............. 25 
13. STATISTICAL CONSIDERATIONS ........................................................................................... 25 
13.1 Study Design/Description ..............................................................................................................................  25 
13.2 Randomization/Stratification .........................................................................................................................  25 
13.3 Accrual and Feasibility .................................................................................................................................. 25 
13.4 Primary Objective, Endpoint(s), Analysis Plan .............................................................................................  25 
13.5 Secondary Objectives, Endpoints, Analysis Plans .........................................................................................  26 
13.6 Reporting and Exclusions ..............................................................................................................................  26 
13.7 Evaluation of Toxicity ................................................................................................................................... 26 
13.8 Evaluation of Response ................................................................................................................................ . 26 
13.9 Interim Analysis ............................................................................................................................................ 27 
13.10 Ancillary Studies ........................................................................................................................................... 27 
14. ETHICAL AND REGULATORY CONSIDERATIONS ............................................................. 27 
14.1 Form FDA 1572 ............................................................................................................................................ 27 
14.2 Other Required Documents ...........................................................................................................................  27 
14.3 Institutional Review Board Approval ............................................................................................................ 27 
14.4 Informed Consent .......................................................................................................................................... 28 
14.5 Submission of Regulatory Documents .......................................................................................................... 28 
14.6 Other ..............................................................................................................................................................  28 
15. FINANCING, EXPENSES, AND/OR INSURANCE ................................................................... 28 
R
EFERENCES ........................................................................................................................................... 30 
INFORMED CONSENT ............................................................................................................................ 35 
APPENDIX A ............................................................................................................................................. 45 
APPENDIX B ............................................................................................................................................. 46 
APPENDIX C ............................................................................................................................................. 47 
APPENDIX D ............................................................................................................................................. 48 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
1
 1. OBJECTIVES  
 
1.1 P rimary Objective  
 
 To determine the safety of Berberine administered to participants with UC in clinical remission while receiving 
maintenance therapy with Mesalamine. 
 
1.2 Secondary Objectives  
 
 D
etermine the molecular efficacy of Berberine by examining the following biomarkers:  
 Plasma-based measures of inflammation, including the blood C-reaction protein (CRP) level, erythrocyte 
sedimentation rate (ESR), and cytokines such as TNFα, IL-4, IL-6, IL-8 and IL-10 measured by enzyme-
linked immunosorbent assay (ELISA).  
 Tissue-based measures of inflammation, including TNFα, COX-2, and NF-κB by immunohistochemistry 
(IHC), and anti-cancer action, including Ki67 and activated caspase-3 by IHC, and DNA methylation on 
SFRP1, TCERGIL FBN2, TFP12 using the methylation-specific polymerase chain reaction (qMSP ) 
strategy.  
 Clinical Efficacy: UC related symptoms will be measured using the Ulcerative Colitis Disease Activity 
Index (i.e. the Mayo score)  [UCDAI]13, 75. 
 Histological analysis for inflammation: severity of histologic inflammation will be evaluated using the 
Geboes grading system25, 73. 
 Determine plasma concentration of Berberine.  
 
2. BACKGROUND 
 
2.1 Study Disease  
 
C
olorectal cancer (CRC) ranks high in cancer incidence and mortality worldwide, including in the US and China74. 
Specifically, CRC is the third most common type of cancer in both US and China, and accounts annually for ~11% and 
~14% of all cancer deaths, respectively9, 10, 18, 78. Thus, identifying strategies to reduce its incidence is critically important.   
 
U
lcerative colitis (UC) is a chronic intestinal inflammatory process that is clinically characterized by bloody diarrhea, 
fever, weight loss, and anemia1.  Current global incidence and prevalence rates of UC are 8-14 per 100,000 persons and 
120-200 per 100,000 persons, respectively14, with the highest annual incidence of UC at 19.2 per 100,000 person-years in 
N
orth America; it is 6.3 per 100,000 person-years in Asia63, 67. In a case-control study, it was reported that although the 
incidence of UC in the Chinese population is relatively lower compared to Caucasian populations, the risk factors 
associated with UC patients in both populations were similar41. In addition, there was no difference in clinical 
manifestations between Asian and Western countries87. Finally, it is believed that UC incidence in China is falsely low 
due to under diagnosis related to limited health care access, and that concurrent with economic development, access is 
increasing and incidence also appears to be increasing96. 
 
I
ndividuals with UC are at high risk for CRC3, 62, 82 , 83.  Globally, the incidence of CRC in patients with UC is estimated to 
be 2 to 5 times higher than that in the general population of the same age group28. It was reported that the incidence of 
CRC in UC patients in US from 1998 to 2010 was 76.0 per 100,000 person-years30, while in China  from 1990 to 2003 it 
was 30.8102. The vast majority of UC patients are maintained on therapy based upon 5-aminosalicylic acid (5 -ASA)20, 21.  
However, although Mesalamine, the 2nd generation of 5-ASA,  effectively reduces periods of active disease and extends 
r
emission time4, 59, UC often becomes refractory, and with prolonged UC, there is an increased risk of CRC (2% at 10 yr., 
8%
 by 20 yr., and 18% by 30 yr.)40. Other available medical treatments, such as biological agents or immunosuppressants, 
are not only expensive, but are associated with potential adverse effects like infection and increased risk of malignancy16. 
Moreover, once CRC develops, treatment remains suboptimal and its prognosis is poorer for patients with UC compared 
to those without38. Therefore, the development of new therapies that combine high treatment efficacy, convenient dosing, 
low side effects, and, more importantly, with CRC chemopreventive ability, is an important goal for UC management and 
its associated CRC incidence reduction.  
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
2
 2.2 Study Agent 
 
B
erberine is a main constituent of Coptidis rhizome.  A large body of evidence demonstrates that it inhibits colorectal 
carcinogenesis in humans, mainly through its anti-inflammation effects. Berberine is widely used to treat gastroenteritis 
and diarrhea in China17, 19, 55 , 80. In two clinical trials in adult patients with acute diarrhea, Rabbani reported the efficacy 
and safety of Berberine70, 71. In another clinical trial on acute watery diarrhea, Berberine was found to be as effective as 
tetracycline47.  In chloroquine resistant malaria, the combination of pyrimethamine and Berberine has been shown to 
optimally clear the parasite and reduce gastroenteritis symptoms77.  Across different animal models of intestinal 
inflammation, Berberine is efficacious99, 101, 104.  Of high importance, Berberine inhibits colon carcinogenesis in preclinical 
models. It has high activity in dextran sulphate sodium (DSS) and in trinitrobenzene sulfonic acid (TNBS) induced colitis 
in mice and rats31, 57, 94, 103. Furthermore, it prevents azoxymethane (AOM)-induced colon carcinogenesis in rats81 with 
suc
h effects being largely attributed to the anti-inflammatory properties of Berberine.  Although not entirely clear, several 
lines of evidence support the notion that a primary effect of Berberine on the intestine relates to anti-inflammatory 
activity. In China, Berberine is widely used clinically to treat a range of inflammatory ailments, while specific anti-
inflammatory activity has been demonstrated across of variety of models. Specifically, Berberine is efficacious in 
adjuvant-induced murine models of arthritis and in experimental models of osteoarthritis in the rat33, 34, 48, 52, 96. It 
suppresses autoimmune nephritis in BALB/c mice64 and attenuates lipopolysaccharide-induced extracellular matrix 
ac
cumulation and inflammation in rat mesangial cells42. In addition to these  rigorously conducted and physiologically 
relevant studies, Berberine’s basic anti-inflammatory action has been loosely linked to a number of downstream 
processes, including anti-oxidatic, anti-apoptotic, and anti-tumor activities in a wide array of reports (reviewed in37, 84). 
However, the design of such studies (typically involving very high concentrations of agent in vitro), places severe 
limitations on the meaning of resultant findings.         
 
In considering the focus of this proposal on a Chinese population, it is important to consider that extensive safety 
information is available about the clinical use of Berberine in this cohort and is lacking in a US-based cohort. This is 
critical information in that drug safety is a central tenant of chemoprevention. Because genetic factors are major 
determinants of drug metabolism, thus underlying the field of pharmacogenomics, toxicity information cannot readily be 
extrapolated across populations. In addition to Berberine’s wide spread clinical use in China, multiple clinical trials 
carried out in Asian populations indicate that Berberine (1.0 – 1.5 g daily for 3 months) is safe in this coho rt51, 87, 97, 100.  A 
se
parate revealing trial focused on patients with radiation-induced acute intestinal injury (RIAII); it randomized patients to 
300mg Berberine orally three times daily versus control for three weeks58. The incidence, severity, and time to occurrence 
of RIAII were all significantly reduced by Berberine. Further, toxicities were lower with Berberine. The study indicated 
that oral Berberine was feasible, well tolerated, and effective58. Importantly, as RIAII is caused not only by death of the 
endothelial cells, but also by leukocyte recruitment and inflammatory response, RIAII mimics the active process of UC. 
As a traditional drug widely used for thousands of years in China, this CFDA (China Food and Drug Administration)-
approved drug has been manufactured into an over-the-counter drug in China, formulated as tablets or capsules.  The 
therapeutic dosage for most clinical situations is 300 mg orally two to four times daily61. Presently, Berberine is available 
as a dietary supplement in the form of 100-200 mg capsule dosage per day in the US, but it is not officially approved by 
the Food and Drug Administration (FDA) in the US. Based upon above findings, we hypothesize that Berberine will be 
safe and beneficial in UC patients, and that its administration to a Chinese cohort will be safe.  
 
Some human studies have examined blood Berberine concentrations. In one study, 400 mg of oral Berberine gave a mean 
maximum plasma concentration (Cmax) of 0.4 ng/ml35. In another, 300 mg oral Berberine per day for 7 days gave a mean 
steady-state plasma concentration of 0.3 ng/ ml98. Of high potential importance, current findings indicate that oral 
B
erberine will provide for efficient delivery of agent to the target organ (i.e., the colorectum) with low exposure to 
systemic organs. Selective delivery to target organs uses pharmacology to optimize efficacy and minimize systemic 
toxicity, and is a highly desirable strategy for chemopreventive agents. Specifically, murine-based studies demonstrate 
that the oral bioavailability of Berberine is below 0.000%46. Also, a plateau in blood concentration was seen with 
increased oral doses. Of notable interest, intraperitoneal injection led to blood concentrations that were 20% of those of IV 
injection. These findings suggest that Berberine is absorbed through the intestinal lining (and is thus delivered to colonic 
epithelium and the supporting organ), but undergoes rapid first pass metabolism in the liver. Together, these findings 
further support our hypothesis that Berberine will be safe and beneficial in UC patients. 
 
The ideal chemopreventive agent, in addition to being efficacious in the prevention of cancer, must be easily 
administered, affordable, safe, and well tolerated, with minimal side effects. Thus, Berberine holds great promise as an 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
3
 efficacious chemopreventive agent for patients with UC who are at high risk for CRC. Because essentially all of those 
diagnosed with UC are maintained on Mesalamine, the first step in exploring Berberine’s chemopreventive efficacy is to 
formally assess the safety of Berberine when administered to patients maintained on Mesalamine. There are no recognized 
contraindications for administering Berberine to UC patients maintained on Mesalamine and Chinese physicians do so 
under clinical circumstances. While it is reassuring that there are no reports of adverse interactions it needs to be 
underscored that the safety and efficacy of Berberine administered to a UC cohort maintained on Mesalamine has not yet 
been examined.  
 
Therefore, we propose a randomized, placebo-controlled, phase I pilot study to investigate the safety of Berberine in a 
group of Chinese patients with UC in clinical remission while receiving maintenance therapy with Mesalamine. As such, 
this study will provide the necessary safety information to support future expanded investigation on Berberine as a CRC 
chem
opreventive agent in UC patients. It will also generate pilot biomarker information that will directly support the 
design of future studies.  Recognizing that an important parallel goal is to assess the feasibility of conducting early phase 
cancer chemoprevention trials in China, the proposed study is purposefully designed to be small and pilot in nature. The 
proposed study therefore represents an important first step in determining whether Berberine can provide protection for 
UC patients who are at risk for a common cancer and a common cause of death. It also represents an important first step 
in conducting studies in a country whose unique qualities and opportunities, including a well-established medical system 
for clinical trials, large populations, high density of patients in large hospitals (allowing for time- and cost-efficient 
recruitment), provide a highly leveraged opportunity to advance the field of chemoprevention in a manner that will 
directly improve the health of people who reside in the US.  
 
2.3 Rationale  
 
B
erberine is efficacious against UC 
The pathological features of UC are marked by inflammation, with infiltration of neutrophils and lymphocytes in the 
mucous membranes, which is believed to underlie the characteristic mucosal ulcerations1.  Many different animal models 
of UC have been developed90. Both DSS- and TNBS- induced colitis are well-established rodent animal models of 
mucosal inflammation that have been used for over two decades to study UC pathogenesis and to support preclinical 
studies69, 89. Consistent with UC serving as a CRC risk factor, these same models are used to study colitis-associated 
carcinogenesis12, 15, 44. Moreover, changes in pro-(TNF-α, NF-κB, IL-6, IL-8) and anti-inflammatory (IL-10, IL-4) 
cytokine levels in these models emulate those observed in humans with UC85.  Furthermore, therapeutic efficacy in these 
models, especially DSS-induced colitis, has been shown to accurately reflect efficacy in humans65. In both TNBS-induced 
colitis and DSS-induced colitis murine models, Berberine decreases colitis31, 57, 103, and this is accompanied by induction 
of colonic macrophage apoptosis94, and by inhibition of pro-inflammatory cytokine production and related signaling 
pathways in colonic macrophages and epithelial cells through suppressing the Nuclear factor-kappaB (NF-κB) pathway8, 
31
, 57, 94 , 103. In addition, in macrophage-based experiments, Berberine was reported to inhibit inducible cyclooxygenase-2 
(COX-2) expression, which in turn abolish es pro-inflammatory responses39. These findings demonstrate that Berberine 
i
nhibits pro-inflammatory processes and decreases colitis in established preclinical models of UC that have a track record 
of predicting efficacy in humans. Although it is unclear whether these molecules are primary or secondary factors 
involved in the regulation of the inflammation, they can be considered as biomarkers to test the drug efficacy and monitor 
inflammation severity. We hypothesize that Berberine will suppress these markers of inflammation in humans.  
 
Berberine inhibits carcinogenesis 
There is increasing evidence showing that Berberine inhibits inflammation-triggered carcinogenesis24, 26. In murine 
experiments, Berberine was found to significantly inhibit carcinogenesis induced by 20-methylcholanthrene or N-
nitrosodiethylamine (NDEA) in a dose-dependent manner2. In addition, it was reported that Berberine prevents the 
appearance of malignant morphology and ultrastructural changes of AOM-induced rat colon cancer81.  These studies 
demonstrate that Berberine protects against chemical carcinogenesis.  Recent studies further demonstrate that Berberine-
induced anticancer effects are strongly correlated with an ti-inflammatory properties through cross talk between different 
targeted signaling pathways, such as the NF-κB pathway for anti-inflammatory effects and caspase-dependent pathways 
for apoptosis54, 69. Specifically, it is reported that Berberine suppresses the NF-κB pathway and inhibits COX-2 
transcriptional activity effectively in a dose-dependent and time-dependent manner in colon cancer cells23, 78, 92, 93. By 
modulating the abnormal signaling pathways in cancer cells11, 23 , 60, 78, 79, Berberine blocked the proliferation of and 
i
nduced death in multiple cancer cell types in vitro and in vivo2, 7, 22 , 27 , 32, 36, 45, 91.  Chemoprevention of CRC is already 
possible with celecoxib, although it is still not the ultimate drug of choice, especially because of the cardiovascular risk 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
4
 associated with COX-2 inhibitors5. With cardiovascular system protective effects50, 56, we hypothesize that Berberine 
could be developed into an effective chemopreventive agent for CRC. 
 
Primary Objective: 
 
Objective:  To determine the safety of Berberine administered to participants with UC in clinical remission while receiving 
maintenance therapy with Mesalamine. 
 
Hypothesis: Berberine will be well tolerated by UC subjects in clinical remission .   
 
Techniques for Endpoint Evaluation:  Toxicity will be measured at study visits using the NCI criteria and recorded in case 
report forms. In addition to assessing clinical toxicity, we will collect tissue and blood samples from recruited participants 
at the beginning of the trial and at the end of Berberine administration (three months later) and evaluate organ toxicity by 
standard clinical chemistry tests. Finally, we will observe and record symptoms such as fever, fatigue, weight loss, 
appetite, stool frequency, bloody stool and other upper and lower gastrointestinal tract symptoms in participants. 
 
Secondary Objectives:    
 
Objectives: 
 Determine clinical  efficacy by measuring UC related symptoms.  
 Determine the molecular efficacy of Berberine by examining blood- and tissue-based biomarkers of inflammation, 
apoptosis and DNA methylation. 
 Examine the severity of inflammation using histologic analyses. 
 Determine plasma concentration of Berberine.  
 
Hypothesi s: Berberine will inhibit inflammation pathways (as evidenced by the suppression of pro-inflammatory markers) 
and decrease ulcerative colitis, making it a potentially effective chemopreventive agent for CRC. 
 
Techniques for Endpoint Evaluation:  
 Clinical efficacy : Clinical efficacy will be measured using the UCDAI  score13, 74. UCDAI assessment is a well-
r
ecognized standard assessment that can be reproducibly performed by endoscopists at Xijing Hospital. 
 
 Measures of inflammation: 
 Blood-based measures of inflammation: Biomarker analysis will be conducted using commercially 
available ELISA kits for TNFα, IL-4, IL-6, IL-8 and IL-10 KIT (R&D Systems, Minneapolis, MN) 
according to the manufacturers’ specifications. Other plasma-based measures of inflammation, including 
the blood CRP level and ESR will also be assessed. 
 
 Tissue-based measures of inflammation and anti-cancer action : Inflammation-related biomarkers (TNFα, 
COX -2, and NF- κB) and anti-cancer action biomarkers (Ki67 and activated capsase-3) in colorectal 
biopsy tissue will be evaluated by IHC. DNA methylation on SFRP1, TCERGIL FBN2, and TFP12 using 
qMSP strategy will also be performed. 
 
 Histological analysis of inflammation: Patients in clinical remission from UC still frequently have 
histologic features of inflammation, which correlate with endoscopic appearance72.  We will 
ut
ilize the same procedures for tissue acquisition, fixation and pathologic examination as 
described previously72. Six of the seven colon biopsies will be embedded for histology and 
i
mmunohistochemistry. Histologic sections will be stained with H&E and the severity of 
histologic inflammation will be evaluated using the Geboes grading system25, 72.  
 
 Immunuhistochemical analysis of inflammation : Six of the seven colon biopsies will be embedded 
for histology and IHC.  IHC has the advantage of allowing identification of the cells being probed 
but has the disadvantage of being semi-quantitative with regards to intensity and expression.  
Colonic epithelial apoptosis and cell proliferation will be determined by cleaved caspase-3 and 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
5
 Ki-67, respectively.  Caspase-3 and Ki-67 will be assessed using IHC since the percentage of 
positive cells is the gold standard for reporting these results.  Cleaved caspase-3 and Ki-67 are 
robust, well-validated measures of these parameters.  TNFα, COX-2, and NF-κB will also be 
assessed by IHC.  For this, we will use computer-aided quantitation to improve the robustness of 
expression analysis. 
 
 DNA methylation: One of the seven colon biopsies will be used for DNA methylation analysis. 
DNA methylation has been reported to be correlated with the development of colitis-associated 
cancer.  It has been reported that the methylation status of selective genes (SFRP1, TCERG1L, 
FBN2 and TFPI2) could be used as a risk marker for colon cancer in UC patients49.  Methylation 
ana
lysis will be performed using the MSP strategy, as previously described29. Changes will be 
com
pared with qMSP.  The current study provides an opportunity to validate these associations, 
potentially leading to a means to identify high risk individuals with UC for progression towards 
colon cancer. 
 
 Blood Berberine concentration measurement: Berberine concentrations with be measured using high-performance 
liquid chromatography /mass spectrometry (HPLC/MS).  
 
 Blood Count and Blood Chemistry:  Blood will also undergo standard clinical testing for complete blood count and 
blood chemistry to evaluate for end organ function.  
 
Target Population 
The goal of this Phase I trial is to determine the safety of Berberine, in subjects with UC in clinical remission and 
maintained with Mesalamine, therefore, the target population would be patients with UC in clinical remission, regardless 
how long they were diagnosed for UC.   Entry criteria w ill consists of patients  (age 18 – 70) with UC in clinical remission 
(UCDAI , Appendix A ) ≤ 1 for ≥ 3 months) who are receiving maintenance therapy with  Mesalamine. Participants must 
not have had any immunomodulatory treatment or any investigational agents within the past 3 month  or t ak e medicines 
that are inducers , inhibitors or substrates of select CYP isozymes (see Appendix B) within the past 3 months.  
 
Why this trial is important 
Prevention of CRC by administration of chemopreventive agents is one of the most promising options for decreasing CRC 
mortality, and especially so for high risk UC patients. Successful implementation of a chemopreventive strategy depends 
not only on accurate identification of high-risk populations, but also on the development of safe and effective drugs 
suitable for use in those specific populations. Despite this need, effective agents are lacking, and the field is searching for 
novel acting candidates. Berberine has a long history of use for anti-inflammatory ailments, lacks significant side effects, 
and has efficacy in relevant models of colitis and colorectal carcinogenesis, and as such it constitutes a novel agent with 
high potential as a chemoprevention drug for UC patients. Further, oral Berberine achieves high accumulated 
concentration to the target organ (i.e., the colonic lumen), while sparing systemic organs (and the associated toxicity), thus 
providing a highly desirable scenario for a chemopreventive agent. As such, Berberine also has potential use as a CRC 
chemopreventive agent in the general population. Although the body of preclinical in vitro and in vivo evidence is 
compelling for efficacy in UC, no controlled clinical trials have been carried out in human patients affected by UC. As the 
chemoprevention effects of Berberine currently remain preclinical, it is necessary to carry out such trial.  
 
Why this study is being implemented in China   
We have extensively discussed our plan to implement this study in China throughout the leadership of the Division 
Cancer Prevention (DCP), inclusive of its Director, Dr. Barry Kramer, and there is thematic support. Inclusion of China 
was highlighted by Dr. Kramer as important for the field of cancer prevention (AACR Frontiers of Cancer Prevention 
2013 Special Lecture, “NCI Division of Cancer Prevention: Where we are and where we are headed”). Aside from 
thematic alignment with the stipulated goals of DCP, there are several reasons specific to this proposal. Berberine has 
been extensively used in China. Thus, Chinese physicians are intimately familiar with its use. A key related point is that 
its safety profile is well understood in the Chinese cohort. As the safety of chemopreventive agents is paramount, our 
proposed development plan provides an optimal pathway to evaluate agent efficacy, while optimizing patient safety. The 
scientific rational for this proposal was generated by the very people who will be conducting it. Alignment of those who 
generate an idea and preliminary supportive data with those who conduct a clinical trial has always been deemed optimal, 
and is universally recognized as such by review panels, and the general scientific community. Xijing Hospital of Digestive 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
6
 Diseases in Xi’an constitutes an optimal clinical site. This hospital is completely dedicated to diseases of the 
gastrointestinal tract. In China, it has been continuously ranked as No 1 in the past 5 years in the gastrointestinal disease s 
field. It is world renowned for its expertise and scientific advances. Its Director, Dr. Daiming Fan is Vice President of the 
Chinese Academy of Engineering.  The Principal Investigator of this study, Dr. Kaichun Wu is a physician 
(gastroenterologist) and scientist, whose research focuses upon UC. Further, he is Chairman of the Department of 
Gastroenterology, Xijing Hospital, and is fully committed to providing the resources necessary to successfully conduct 
this trial. There is a large and established cohort of UC patients within the Department of Gastroenterology, Xijing 
Hospital. Xijing Hospital is part of the Northwestern University Early Phase Chemoprevention Trials consortium, was 
part of the competitive renewal application, and was well received by the review panel. Dr. Raymond Bergan, former 
cons
ortium PI, has extensive knowledge of Xijing Hospital, including its operations and capabilities. He is a Visiting 
Professor there, and co-operates a basic research laboratory there. Dr. Wu and Xijing Hospital’s Department of 
Gastroenterology are committing high levels of resources to support this study. Thus, for a minimal cost to DCP, this 
study and its associated scientific advances can be realized. Further, the advances achieved in this study will serve to 
benefit people in the US. This is because findings from this study will serve to inform us about our ability to 
therapeutically manipulate colorectal carcinogenesis through a novel therapeutic approach. Positive findings can then be 
translated into the US population (a proportion of which are Chinese) from a scientifically informed standpoint.  
 
There are cautionary aspects to implementing a study in China. We have extensively discussed these with DCP Officers. 
Following, we list cautionary aspects and how they will be mitigated:  
 
 Sending U.S. NIH dollars to China under the current fiscal environment is not viewed as highly favorable. Xijing 
H
ospital of Digestive Diseases is providing financial support for all China-based costs. No U.S. dollars will be 
se
nt to China.  
 
 China is far away, making trial monitoring difficult, and this site has no experience in conducting 
chemoprevention trials. We are highly respectful of these facts and their implications. Therefore, the plan is to 
implement a very small pilot trial. A main goal is to demonstrate the feasibility of implementing a DCP study at 
this site. The Northwestern consortium and Dr. Bergan in particular, has an established track record of 
successfully working with sites and investigators who are new to the field of cancer chemoprevention. As such, 
Dr. Bergan has successfully brought new investigators into the field, which is widely deemed as critically 
important for the field. He now aims to do so for China, similarly deemed as important. Extensive monitoring of 
the site will be conducted. It will be monitored on site four times per year by Dr. Bergan (two times he will be 
accompanied by a Northwestern-based study monitor). Dr. Bergan has extensive interactions with China, and Dr. 
Lifang Hou (consortium co-PI) was trained as a physician in China, frequently travels there, has conducted 
several trials in China, and has successfully shipped clinical samples from China to the US. Finally, tissue 
endpoint biomarkers will be analyzed in China, and will then undergo complete re-analysis in the US by a GI 
pathologist, Dr. Guang- Yu Yang, thus providing rigorous quality control (QC). Dr. Yang is a US trained and 
practicing physician/scientist, whose research focuses upon colon carcinogenesis and its modulation by 
chemoprevention agents. Further, as a native born Chinese, he is well poised to ensure communication and QC in 
the realm of tissue processing.  
 
 A minor issue was raised about the currently unpopular nature of investigating natural products for cancer 
prevention, and the fact that Berberine is a natural product. In this regard, it is important to consider that many 
non-natural products have also failed in cancer chemoprevention trials. Further, the majority of all FDA approved 
small molecule drugs are in fact natural products or directly inspired by them105. Specifically, for FDA approved 
small molecule drugs for cancer between 1/1981 and 12/2010, eighty percent were natural products or directly 
inspired by them.The fact is there is a large body of preliminary data related to Berberine to support its 
investigation for colorectal cancer, and there is a need for novel agents for exactly this purpose. Finally, a major 
asset of China is its rich source of bioactive agents. Such natural products have transformed the treatment of such 
unlikely diseases as acute promyelocytic anemia, where the Chinese natural product arsenic trioxide is now in 
widespread clinical use in the US75.  
 
 
3. 
SUMMARY OF STUDY PLAN  
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
7
 This is a single center, double -blind, randomized, placebo -controlled, pilot study . The goal of this Phase I trial is to 
det
ermine the safety of Berberine  in subjects with UC in clinical remission  and m aintained with Mesalamine .  Pilot 
information about Berberine ’s ability to modulate relevant biomarkers at the dose being assessed will also be gathered.   
 
Subjects will be randomized in a double-blind fashion to 300 mg T I D Berberine  (12 subjects) versus placebo (4 subjects), 
for 3 months.   Two additional participants are anticipated to be accrued ( for a total of 18 subjects) t o account for an 
anticipated dropout  rate of 10%.  I n order to keep the numbers in either treatment group as planned, dropouts in either 
treatment group will be replaced by subjects assigned to that same treatment and gender group.  Assuming an accrual rate 
of approximately 1.5 per month, we e xpect the stu dy to be completed in 12 months.   
 
Subjects will be enrolled and followed up at Department of Gastroenterology, Xijing Hospital, Xi’an, China.  For t h ose 
subjects experiencing grade 2 toxicity felt to be due to Berberine , the dos age will be successively decreased by 100 mg 
decrements per dose until resolution (note, given TID dosing, this translates to 300 mg/day decrements).  T hose not 
tolerating 300 mg/day, will be removed from study, as will those experiencing grade 3 or 4 to xi city at any dose . 
C
ompliance will be assessed by  pill counts and diary reviews at monthly cl inical visit s.and by measuring plasma 
Berberine  concentrations  at  the end of the trial. Subjects whose compliance is below 80% will be removed from study.   
 
Colorectal biopsies and blood samples will be taken at the initial visit (pre-treatment). At the end of the 3-month 
treatment, subjects will repeat earlier screening assessments to determine the outcomes of the primary and secondary 
objectives.  One month post study, subjects will be contacted by clinical visit to assess symptoms.  
 
 
4. PARTICIPANT SELECTION 
 
4.1 Inclusion Criteria 
 
4.1.1
 Patients with ulcerative colitis in clinical remission (UCDAI , Appendix A ) ≤ 1 for  at least 3 m onths) , reg
ardless of 
how long  ago they were diagnosed for UC . 
 
4.1.2 Receiving maintenance therapy with Mesalamine for at least 3 months.  
 
4.1.3  Age 18 - 70 years. Because no dosing or adverse event data are currently available on the use of    
Berberine in participants <18 years of age, children are excluded from this study but will be eligible for future 
pediatric trials, if applicable. 
 
4.1.4 ECOG performance status ≤1 (Karnofsky ≥70%; see Appendix C). 
 
4.1.5 Participants must have normal organ and marrow function as defined below:  
Leukocytes  ≥3,000/microliter 
Absolute neutrophil count ≥1,500/microliter 
Platelets  ≥100,000/microliter 
Total bilirubin  within normal institutional limits.  Higher values (≤ 3 x institutional upper limit 
of no
rmal (ULN)) are acceptable in participants with: 1. known or suspected cholangitis associated with Crohn’s 
disease, or 2, known or suspected inborn errors of metabolism that lead to increased bilirubin.  
AST
 (SGOT)/ALT (SGPT) ≤1.5 × institutional ULN 
Creatinine  within normal institutional limits 
 
4.1.6 Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method 
of birth control; abstinence) prior to study entry and for the duration of study participation, due to unknown, but 
potential risk of Berberine causing uterine contractions and miscarriage37.  Should a woman become pregnant or 
suspect she is pregnant while participating in this study, she should inform her study physician immediately. 
 
4.1.7  Ability to read, understand, and the willingness to sign a written informed consent document. 
 
4.2 Exclusion Criteria 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
8
  
4.2.1 Participants who have had any immunomodulatory treatment in the past 3 months will be excluded. 
 
4.2.2 Participants who have taken any medicines that are inducers, inhibitors or substrates of select CYP isozymes (see 
A
ppendix B) within the past 3 months will be excluded.  Participants who have consumed either grapefruit juice 
or Seville orange juice in the past 7 days will be excluded.   
 
4.2.3 Participants with Dysplasia-associated mass or lesion (DALM) due to longstanding idiopathic inflammatory 
bowel disease will be excluded.  
 
4.2.4 Participants who are currently receiving any other investigational agents or have received investigational agent s 
within the past 3 months will be excluded. 
  
4.2.5 Participants with a history of allergic reactions attributed to compounds of similar chemical or biologic 
composition to Berberine will be excluded. 
 
4.2.6 Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, 
sym
ptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social 
situations that in the opinion of investigators would jeopardize patient safety of data integrity are excluded. 
Individuals who are HIV positive will not necessarily be excluded, will be considered on a case-by-case basis, but 
will be required to meet criteria related to patient safety and data integrity, as assessed by investigators.  
 
4.2.7 Pregnant women are excluded from this study because Berberine has a potential for causing uterine contractions 
and miscarriage37 because there is an unknown but potential risk for adverse events in nursing infants secondary 
t
o treatment of the mother with Berberine, breastfeeding should be discontinued if the mother is treated with 
Berberine.  Women are considered to be of child-bearing potential if they are not surgically sterile or under the 
age 65 and have menstruated within the last two years. 
 
4.3 Inclusion of Women and Minorities  
 
B
oth men and women and members of all races and ethnic groups are eligible for this trial.  
 
4.4 Recruitment and Retention Plan  
 
X
ijing Hospital of Digestive Diseases is solely dedicated to diseases of the gastrointestinal system.  Annually, the hospital 
s
erves over 150,000 outpatients and over 6000 inpatients, performs over 20,000 endoscopic examinations with over 6000 
being colonoscopies. Xijing Hospital of Digestive Diseases has established track records for Inflammatory Bowel Disease 
patients who are being followed-up.   Thus potentially eligible subjects can be identified and contacted prior to the 
procedure. In addition, advertisements will be posted at Xijing Hospital of Digestive Diseases with study contact 
information. Adequate minority participation will be ensured with our patient population.     
 
Once identified, eligible patients will be contacted by the study coordinator who will explain the details of the study and 
the requirements for participation. Patients who are interested in the trial will be given a copy of the IRB approved 
consent form. After the patient signs the consent form, the patient will then be monitored by the research coordinator.   The 
coordinator will be the main contact for patients in accordance with the protocol to ensure pleasant clinic visits.  
Participant retention will be maximized by frequent patient contact.  During each telephone contact and/or clinical visit, 
patients will be assessed for adverse events and counseled on AE management and the use of rescue medication.  
Compliance will be assessed by  pill counts and diary reviews at monthly cl inical visit , and by measuring plasma 
Berberine concentration  at the end of the trial.   
 
N
orthwestern University will work closely with Xijing Hospital of Digestive Diseases on an ongoing basis to monitor 
recruitment and adjust or employ new strategies as needed to maximize patient recruitment with an emphasis on ensuring 
a balanced representation of women and men.   This assistance will include coordinating recruitment material design and 
pl
acement.  
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
9
 Participants will not be reimbursed for participation, but all of their clinical test cost will be covered, including the 
Mesalamine that will be taken during the trial periods. 
 
 
5. AGENT ADMINISTRATION 
 
I
ntervention will be administered on an outpatient basis. The initial treatment will be 300 mg TID; if this is not tolerated, 
the dosage will be decreased by 100 mg/dose (300mg/day) until a tolerable dosage is reached.  Reported adverse events 
(AEs) and potential risks are described in Section 6.2.  
 
5.1 Dose Regimen and Dose Groups 
 
16 participants will be randomized into one of two groups: 12 participants will receive 300 mg Berberine three times per 
day; 4 participants will receive placebo tablets three times per day.  Two additional participants (for a total of 18 
participants) are anticipated to be enrolled to account for an anticipated dropout rate of 10%.  In order to keep the numbers 
in either treatment group as planned (3:1), dropouts in either treatment group will be replaced by subjects assigned to that 
same treatment and gender group.  Dosing will extend for 90 days.  
 
5.2 B erberine  Administration  
 
Participants will take 300 mg three times per day (3 x 100 mg tablets, three times a day) of Berberine for a period of 90 
days.  Participants should take tablets within one hour after a meal with water every 6-8 hours. Patients will be asked to 
return to the clinic within 6 days of the initial screening visit to pick up the study medication. If patients are unavailable to 
return to the clinic within this timeframe to pick up the study medication, the study medication may be shipped to the 
participant’s home. Three (3) bottles (each containing 120 tablets) will be distributed initially and 3 bottles will be 
distributed at the Day 30 and Day 60 visits.  An additional bottle may be dispensed if needed. 
 
5.3 Run-in Procedures   
 
N/A 
 
5.4 Contraindications 
 
N
one, other than pregnancy or unprotected intercourse for females of childbearing potential as Berberine has a potential 
for causing uterine contractions and miscarriage.  
 
5.5 Concomitant Medications 
 
A
ll medications (prescription and over-the-counter), vitamin and mineral supplements, and/or herbs taken by the 
participant will be documented on the concomitant medication CRF and will include: 1) start and stop date, dose and route 
of administration, and indication. Medications taken for a procedure ( e.g., biopsy) should also be included. Participants 
must
 not take any medicines that are inducers, inhibitors or substrates of select CYP isozymes (see Appendix B) within 
the past 3 months.  Participants must not take over-the-counter berberine during the trial.   
 
5.6 Dose Modification 
 
The initial treatment will be 300 mg TID. Toxicity will be graded acc o rding to the NCI CTCAE version 4.0.  For t hose 
subjects experiencing grade 2 toxicity felt to be due to Berberine , dosage will be successively decreased by 100 mg 
decrements per dose  (i.e. take fewer pills)  (note, given TID dosing, this translates to 300 mg/day decrements) .  If after one 
week the participant is still experiencing a grade 2 toxicity related to Berberine  with the reduced dose, the dose will 
continue to be decreased  (at one week intervals)  unt il a tolerable dosage is reached  (< grade 2  toxicity related to 
B
erberine ). Those not tolerating 300 mg/day, will be removed from study, as will those experiencing grade 3 or 4 toxicity 
(related to Berberine) at any dose .  The dose will not be ‘interrupted’ other than stopping the drug to go off th e s tudy.  
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
10 5.7 Adherence/Compliance 
 
5.7.1  If less than 80% of the dose has been consumed during the study period, the subject will be considered non-
compliant.  All participants that receive a study agent for any period of time will be evaluable for efficacy and 
toxicity.  Participants will not be replaced. 
 
5.7.2 Clinical visits will be made each month to monitor compliance. Pill counts will be performed and patient diary 
will be reviewed at each clinical visit. Drug levels will be measured in blood on the last day of administration. 
 
 
6. PHARMACEUTICAL INFORMATION 
 
6.1 Study Agent  
 
B
erberine (C 20H18NO 4, molecular weight 353.36 Da), a natural plant alkaloid, is found in the roots, rhizomes, and stem 
bark of many plants and has been widely used to treat gastroenteritis and diarrhea in China 88, 97. There is increasing 
evidence that it inhibits carcinogenesis primarily through anti-inflammatory action 53. For this study, Berberine isolated 
from the Coptidis  rhizome is supplied by Shanghai SINE TianPing Pharmaceutical Co. (Shanghai, China).   
  
T
he investigational product to be used in the proposed clinical investigation is a film-coated tablet with a yellow core 
delivering 100 mg Berberine. Tablets allocated for this study met the requirements and standards from the Pharmacopoeia 
of the People’s Republic of China (2010), are >98% pure, and have an expiration date of May 10, 2017 (Shanghai SINE 
TianPing Pharmaceutical Co. Ltd. Berberine Hydrochloride Testing Report, December 2, 2013). Additional supply with a 
later expiry date will be made available if the intervention phase of the study has not completed by that time. M atching 
placebo tablets  will also be supplied by Shanghai SINE TianP ing Pharmaceutical Co. Ltd.  
 
6.2 Reported Adverse Events and Potential Risks 
 
B
erberine is available as a dietary supplement at doses of 100 to 200 mg/day in the US and has been approved by the 
Chinese Food and Drug Administration (CFDA) for diarrhea at a dose of 300 mg tid. Predominant clinical uses of 
B
erberine include treatment of bacterial diarrhea, intestinal parasite infections, and ocular trachoma infections 68. 
Additionally, Berberine has been investigated for treatment of type 2 diabetes, cardiovascular disease, hyperlipidemia, and 
cancer. In clinical studies for these indications, oral doses as high as 1500 mg Berberine/day for three months were 
administered51, 87, 97 , 100. No severe adverse effects and no significant changes in plasma kidney and liver parameters were 
observed in any of the studies. Mild to moderate constipation was seen in 3−8% of subjects. In a study using 300 mg 
Berberine TID for 30 days in patients with acute coronary syndrome, three of the 61 patients discontinued treatment due 
to abdominal pain, rash, or constipation66.  
 
As most Berberine-containing plants are considered uterine stimulants, they should be used with care during pregnancy6. 
 
Berberine has not been shown to be genotoxic and does not induce significant cytotoxic, mutagenic, or recombinogenic 
effects6. The intravenous lethal dose for 50% (median) of test animals (LD 50) of Berberine sulfate in mice is 
approximately 25 mg/kg, while intravenous administration of Berberine to dogs at doses up to 45 mg/kg does not produce 
gross toxic effects.   
 
6.3  Availability 
 
B
erberine and matching placebo will be manufactured and supplied by Shanghai SINE TianPing Pharmaceutical Co ., 
Shanghai, China. Berberine  and matching placebo will be packaged in bottles containing  120 tablets.  
 
6.4 Agent Distribution  
 
Shanghai SINE TianPing Pharmaceutical Co . will manufacture the B erberine  tablets and matching placebo tables and 
supp l
y them to the clinical site  (Department of Gastroenterology, Xijing Hospital, Xi’an, China ).  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
11  
X
inyan Jiang, at Shanghai SINE TianPing Pharmaceutical Co , will be contacted for ordering  (E-m ail:  cz_xn@aliyun.com , 
cell phone: +8618019168035).   
 
6.5  Agent Accountability 
 
T
he Protocol Lead Investigator, or a responsible party designated by the Protocol Lead Investigator, must maintain a 
careful record of the inventory and disposition of all agents received from Shanghai SINE TianPing Pharmaceutical Co . 
usi
ng the NCI Drug Ac countability Record Form (DARF) . The Protocol Lead Investigator is required to maintain 
adequate records of receipt, dispensing, and final disposition of study agent. This responsibility has been delegated to  
Department of Gastroenterology, Xijing Hospital . The research pharmacis t at Xijing Hospital i s Ms. Ying Song, who can 
be reached at 251653125@qq.com , phone: +86-15339072373.   
 
Include on the receipt record from whom the study agent was received and to whom it was shipped, date, quantity, and 
batch or lot number. On the dispensing record, note quantities of and dates when study agent was dispensed to and 
returned by each participant.   
 
6.6 Packaging and Labeling 
 
B
erberine and placebo tablets will be packaged, labeled and distributed by Shanghai SINE TianPing Pharmaceutical Co. 
Ltd, Shanghai, China. Tablets are packaged in 1 20-count  bottles.   
 
Each bottle will be labeled with a one-part label identifying study specific information, such as study title, DCP protocol 
number, dosing instructions, recommended storage conditions, the name and address of the distributor, randomization 
number, and a caution statement indicating that the agent is limited by China law to investigational use only and the agent 
should be kept out of reach of children.  
 
6.7 Storage 
 
T
he Berberine tablets that will be used in the study are stable when stored at room temperature (15 to 25 ºC) in an air-
conditioned space for until dispensed to subjects. Once dispensed, the subjects will be instructed to store the drug in their 
homes protected from light, heat and moisture.  If the results of stability tests at any time points are getting close to the 
limits of specification, we will contact Shanghai SINE TianPing Pharmaceutical Co. Ltd, to prepare a new batch for the 
clinical trial. 
 
6.8 Registration/Randomization 
 
A
 study coordinator must forward to Northwestern via the Northwestern Oncology Trials Information System (NOTIS), a 
signed and complete informed consent and a completed eligibility checklist for each participant identified as eligible to be 
entered into the study.   
 
All participants must be registered with the Northwestern University Clinical Research Office within 24 hours of 
enrollment.   
 
After registration, participants will be randomized by the Quality Assurance Monitors at Northwestern Lurie Cancer 
Center to either treatment with Berberine or placebo.  The purpose of the placebo assignment is to allow evaluation of the 
perception of subtle, sub-clinical effects that might be associated with trial participation.  Investigators and participants 
will be blinded as to the result of randomization. The following people will be un-blinded:  The study statistician, the 
Lurie Cancer Center Quality Assurance Monitors, and the Investigational pharmacist at Xijing Hospital. The study 
st
atistician will set up randomization blocks, as previously described.   
 
Full unblinded randomization information will be faxed to Xijing Hospital research pharmacist at: 86-298-253-9041. The 
cl
inical research coordinator will receive a blinded Participant ID code for the patient via fax. Participants must not start 
protocol treatment prior to randomization with Northwestern.   
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
12 6.9 Blinding and Unblinding Methods 
 
Study participants will receive a prescription, blinded, from the investigational pharmacy at Xijing Hospital. Unblinding 
will only occur when it is deemed medically necessary and will only take place after consultation with the NCI, DCP 
Medical Monitor: 
 
DCP Medical /Scientific Monitor  
Luz Maria Rodriguez, MD, FACS 
NCI/Division of Cancer Prevention  
9609 Medical Center Dr 
Rm 5E-228 
Telephone (240) 276-7039  
Fax (240) 276-7848  
Em
ail: rodrigul@mail.nih.gov 
If the medical monitor is unavailable or if after hours consultation is needed, please contact Dr. Seema Khan, at telephone: 
312-503-4236, or cell : 312-307-3646. 
 
6.10 Agent Destruction/Disposal 
 
At the completion of the investigation, all returned or unused study agent will be disposed of according to institution-
specific policy and procedures for handling investigational agents.  Both Xijing hospital and Northwestern University will 
maintain a record of what is destroyed including name of agent, quantity, lot number and expiration date.  All records will 
be maintained for 5 years from when the study is completed. 
 
7. CLINICAL EVALUATIONS AND PROCEDURES 
 
7.1 Schedule of Events 
 
 
 
 
 
Evaluation/ Procedure  
 
Screening  
Randomization  
Day 0 * 
Day 7  
(+/- 3 days)  
Day 30  
(+/- 3 days)  
Day 60  
(+/- 7 days)  
Day 90  
(- 7 days)  
Day 120  
(+/- 7 days)  
or Early 
Termination  
Informed Consent  X        
Assess Eligibility  X X       
Medical History  X        
Physical  Exam  X    X X X X 
Vital Signs, Height and 
Weight1 X    X X X X 
Baseline Symptoms  X        
UCDAI Questionnaire  X      X  
Laboratory Tests2 X      X  
Rectal Biopsy3 X      X  
Research Blood 
Collection4 X      X  
Concomitant Medications  X  X X X X X X 
Dispense Study Agent   X   X X   
Pill Count     X X X X  
Review Agent 
Diary/Record     X X X X  
Adverse Events    X X X X X X 
Telephone Contact5   X X     
Collect Study Agent        X  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
13  
1. V
ital signs assessment is to include pulse, blood pressure, respiration rate, temperature and weight.  Baseline 
assessment must also include height.   
2. CBC, ESR, CRP, and Chemistry Panel (White blood count, RBC count, Hemoglobin, Hct, Platelets, Absolute 
Neutrophil Count, Glucose, Creatinine, Sodium, Potassium, Chloride, SGOT, SGPT, Total Bilirubin, INR).  Baseline 
assessment must include a serum pregnancy test for all women of childbearing potential.  Pregnancy test will only be 
performed at the screening visit. 
3. Colonoscopy with 7 biopsies from inflammatory loci (or from regions close to the initial inflammatory area when the 
patient was first diagnosed). Biopsies taken on day 90 should be ≥5 cm distance from the original biopsy sites. 
4. Research blood collection: 5ml into purple EDTA tube for plasma and 4ml into red top tube for cytokines. 
5. For Day 0, either a telephone contact or an office visit will occur. 
 
*  Participant should begin taking the study medication within 7 days of the screening visit 
 
7.2 Baseline Testing/Prestudy Evaluation  
 
Scre
ening 
 Informed Consent – written informed consent must be obtained prior to any other study procedure. Participants’ 
si
gnature is required on the research informed consent (in addition to the procedure consent) prior to undergoing 
the screening colonoscopy. 
 Participants will be told not to take Berberine for 3 days prior to the screening biopsy.  
 Medical History and Baseline Symptom Review. 
 Concomitant Medication Review – all medications that the participant has taken within the 3 months prior to 
consent are to be recorded. 
 Physical Exam and Vital Signs assessment – vital signs assessment is to include pulse, blood pressure, respiration 
r
ate, temperature and weight.  Baseline assessment must also include height. 
 UCDAI questionnaire to help assess disease state. 
 Inclusion / Exclusion Criteria Review. 
 Clinical Lab Tests (27-31 ml blood) CBC, ESR, CRP and Chemistry Panel (White blood count, RBC count, 
Hemoglobin, Hct, Platelets, Absolute Neutrophil Count, Glucose, Creatinine, Sodium, Potassium, Chloride, 
SGOT, SGPT, Total Bilirubin).  Baseline assessment must include an INR for all patients and a serum pregnancy 
test for all women of childbearing potential.  Women of childbearing potential include those who have not been 
surgically sterilized and have had a period in the past year.  Screening labs must be completed within two weeks 
of registration. 
 Research blood will be collected: Peripheral blood for cytokines analysis (4ml in red top tube) and plasma for 
Berberine concentration analysis (5ml in purple EDTA tube). 
 Colonoscopy with 7 biopsies from inflammatory loci (or from regions close to the initial inflammatory area when 
the patient was first diagnosed).  Each biopsy site will be recorded by denoting the length in centimeters from the 
anal verge to the biopsy site as well as recording position of the participant during time of biopsy (e.g., lying on 
their left side). 
 Register the patient with Northwestern University Clinical Research Office. 
 Provide agent diary (Appendix D) and review it with participant. 
 
Randomization 
 Confirm that the patient meets all inclusion/exclusion criteria. 
 Randomize the patient with Northwestern University Clinical Research Office. 
 Participant will be asked to return to the clinic within 6 days of the screening visit to pick up the study 
medication. Three (3) bottles 100 mg x 120# Berberine tablets/placebo for use as medication will be dispensed.   
 I
f participant is unable to return to the clinic within 6 days, the study medication will be shipped to their home. 
 
7.3 Evaluation During Study Intervention 
 
D
ay 0 
 Telephone contact or office visit with participant with instructions to begin study agent and diary completion.  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
14  Par
ticipants should begin taking the study medication within 7 days of the screening visit.  
 Assess Adverse Events  
 Assess Concomitant Medications  
 
Day 7 (+/- 3 days) 
 Telephone contact with participant 
 Assess study drug compliance  
 Assess adverse events and discuss patient diary  
 Assess Concomitant Medications  
 
Day 30 (+/- 3 days) 
 Physical Exam and Vital Signs assessment – vital signs assessment is to include pulse, blood pressure, respiration 
r
ate, temperature and weight.  
 Assess study drug compliance  
 Assess adverse events and discuss patient diary  
 Assess Concomitant Medications  
 Dispense 3 bottles 100mg x 120# Berberine tablets/placebo for use as medication.   
 
Day 60 (+/- 7 days) 
 Physical Exam and Vital Signs assessment – vital signs assessment is to include pulse, blood pressure, respiration 
r
ate, temperature and weight.  
 Assess study drug compliance  
 Assess adverse events and discuss patient diary  
 Assess Concomitant Medications  
 Dispense 3 bottles 100mg x 120# Berberine tablets/placebo for use as medication.   
 
7.4 Evaluation at Completion of Study Intervention 
 
Part
icipants are to continue taking the study agent for the 90 day study period. All 90-day tests and procedures should take 
place as close to day 90 as possible, but may occur within 7 days of day 90 (from day 83-90) in order to accommodate 
participant conflicts and busy schedules.  
 
Day 90 /-7 days) 
 Concomitant Medication Review  
 Physical Exam and Vital Signs assessment – vital signs assessment is to include pulse, blood pressure, respiration 
r
ate, temperature and weight.   
 UCDAI questionnaire to help assess disease state.  
 Clinical Lab Tests (12-16 ml blood) – CBC, ESR, CRP, and Chemistry Panel (White blood count, RBC count, 
Hemoglobin, Hct, Platelets, Absolute Neutrophil Count, Glucose, Creatinine, Sodium, Potassium, Chloride, 
SGOT, SGPT, Total Bilirubin).   
 Research blood will be collected: Peripheral blood for cytokines analysis (4ml in red top tube) and plasma for 
Berberine concentration analysis (5ml in purple EDTA tube).  
 Colonoscopy with 7 biopsies from same region as, but ≥5 cm from, original  biops i es  taken at screening visit.  I f 
scars are visible from the site of screening biopies, then new biopsies will be taken >/= 5 cm from this site. If they 
are not visible, then biopsies will be taken >/= 5 cm from the prior recorded distance (with the participant in the 
same position as they were in for original biopsies) . 
 Assess adverse events and review patient diary  
 Collect and count study medication from patient  
 
7.5 Post-intervention Follow-up Period 
 
Par
ticipants will be assessed 30 days after their last dose of the study agent for assessment of adverse even ts (participants 
who experienced adverse events will be followed for 30days after their last dose or until all side effects have been 
resolved, whichever occurs later).  For participants who completed the study this visit would occur on day 120.   
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
15 D
ay 120 (+/-7 days) 
 Physical Exam and Vital Signs assessment – vital signs assessment is to include pulse, blood pressure, respiration 
r
ate, temperature and weight  
 Assess adverse events and discuss patient diary  
 Assess Concomitant Medications  
 
7.6 Methods for Clinical Procedures 
 
C
olonoscopies:  The initial colonoscopy will be standard procedure.  The colonoscopy at the end of the trial will be 
research colonoscopy.  At the scheduled day, the patients will come to the endoscopy unit fasting after midnight. On the 
day prior to the exam, the patient will begin a clear liquid diet starting at lunch. The patient will then undergo a standard 
colonoscopy preparation with PEG. This prep is indicated for standard “GI lavage” and contains PEG -4000, sodium 
chl
oride, sodium bicarbonate and potassium chloride for oral solution. After informed consent, the participants will be 
placed on their left side and a rectal exam will be performed. Under conscious sedation, an Olympus video colonoscope 
will be inserted into the rectum and with minimal insufflation of air advanced to the cecum. At the beginning of the tr ial, 7 
biopsies from inflammatory loci will be collected, if applicable. If no such loci are found, 7 biopsies close to initial 
inflammatory area (when the patients were first diagnosed) will be collected. The area of biopsy collection will be 
recorded by denoting the length in centimeters from the anal verge to the biopsy site as well as recording position of the 
participant during time of biopsy. At the end of trial (3 months later), 7 biopsies close to, but ≥ 5 cm away from, this area 
will be collected. Six of these will be fixed in formalin and one will be flash frozen in liquid nitrogen. Specimen collection 
kits will be provided by the pathology department at Xijing Hospital. The study coordinator will arrange to have the 
biopsies processed for H& E sections by submitting to the study pathologists.  
 
Research blood for drug concentration:  5ml blood will be collected (in purple-top EDTA tube) pre-dose (at the 
sc
reening visit) and at 3 months after the start of dosing (at the Day 90 visit) for plasma drug concentration measurement. 
The clinical laboratory of Xijing hospital will provide specimen collection kits with all sample collection, labeling and 
packaging information.  The research blood  will be processed in the clinical laboratory of Xijing hospital.  Al l samples 
will be logged in the lab logbook with the times of arrival to the lab.  Plasma samples w ill be separated immediately by 
centrifugation at 4000 rpm for 3 min and stored at − 80 ˚C  until analysis.   
 
Research blood for cytokine levels:   4 ml of research blood  (in red-top tube)  will be collected a t the pre -study  screening 
v
isit and a t the 3 month visit for cytokines level measurement . The clinical laboratory of  Xijing hospital will provide 
specimen collection kits with all sample collection, labeling and packagin g information.  The research blood  will be 
processed in the clinical labo ratory of Xijing hospital.  All samples will be logged in the lab logbook with the times of 
ar
rival to the lab.  The blood samples will be spun down at 2500RPM for 10 min  immediately upon arrival . Ser um  will be 
al
iquoted before further detection  and stored at -20  ˚C until analysis . 
 
 
8.  CRITERIA FOR EVALUATION AND ENDPOINT DEFINITION 
 
8.1 Primary Endpoint  
 
Safety will be measured at study visits using the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4 
and recorded in case report forms. In addition to assessing clinical toxicity, we will collect tissue and blood samples from 
recruited participants at the beginning of the trial and at the end of Berberine administration (three months later) and 
evaluate organ toxicity by standard clinical chemistry tests. Finally, we will observe and record symptoms such as fever, 
fatigue, weight loss, appetite, stool frequency, bloody stool and other upper and lower gastrointestinal tract symptoms in 
participants. 
 
8.2 Secondary Endpoints 
 
Secondary endpoints will be evaluated in batch once the targeted number of study participants has completed the protocol. 
 
 Clinical efficacy : Clinical efficacy will be measured using the UCDAI  score13, 74. This will be done at the screening 
visit and at the end of the trial (90 day-7days) by an endoscopist. 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
16  
 Blood-based measures of inflammation : Biomarker analysis will be conducted using commercially available enzyme-
linked immunosorbent assay (ELISA) kits for TNFα, IL-4, IL-6, IL-8 and IL-10 KIT (R&D Systems, Minneapolis, 
MN) according to the manufacturers’ specifications. Other plasma-based measures of inflammation, including the 
blood CRP level and ESR will also be assessed. 
 
 Tissue-based measures of inflammation and anti-cancer action : Inflammation-related biomarkers (TNFα, COX-2, and 
NF-κB) and anti-cancer action biomarkers (Ki67 and activated capsase-3) in colorectal biopsy tissue will be evaluated 
by IHC and DNA methylation on SFRP1, TCERGIL FBN2, TFP12 using qMSP strategy. 
 
 Histological analysis of inflammation : Histologic sections will be stained with H&E and the severity of histologic 
inflammation will be evaluated using the Geboes grading system25, 72. 
 
 Blood Berberine concentration measurement: Berberine concentrations with be measured using high-performance 
liquid chromatography /mass spectrometry (HPLC/MS).  
 
 Blood Count and Blood Chemistry:  Blood will also undergo standard clinical testing for complete blood count and 
blood chemistry to evaluate for end organ function.  
 
8.3 Off-Agent Criteria  
 
Par
ticipants may stop taking study agent for the following reasons: completed the protocol-prescribed intervention, 
adverse event or serious adverse event, inadequate agent supply, noncompliance, concomitant medications, or medical 
contraindication. Participants will continue to be followed, if possible, for safety reasons and in order to collect endpoint 
data according to the schedule of events. Subjects who stop treatment for toxicity reason will be followed until the issue is 
resolved or stabilized. If the drop-out rate is higher than expected, we will recruit more participants.  Participants will not 
be r
eplaced. 
 
8.4 Off-Study Criteria 
 
Par
ticipants may go ‘off-study’ for the following reasons:  
 
 Adverse Event  
 Death  
 Disease Progression  
 Lost to follow-up  
 Other  
 Participant Withdrawal  
 Participant Refused Follow-up  
 Physician Decision  
 Protocol Defined Follow-up Completed  
 Protocol Violation   
 Study Complete  
 Ineligible  
 
8.5 Study Termination 
 
N
CI, DCP as the study sponsor has the right to discontinue the study at any time.  
 
 
9. CORRELATIVE/SPECIAL STUDIES 
 
9.1 Rationale for Methodology Selection  
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
17 A
 number of exploratory secondary endpoints will be assessed to guide future chemoprevention studies. 
Clinical efficacy : Clinical efficacy will be measured using the UCDAI  score13, 74. UCDAI assessment is a well-recognized 
standard assessment that can be reproducibly performed by endoscopists at Xijing Hospital. 
 
Blood-based measures of inflammation : The conduct of early phase cancer trials provides the opportunity to evaluate 
systemic drug effect.  Therapy-induced changes in systemic function will be expected to result from changes in cytokines 
expression.  Pre- and post-treatment plasma will therefore be collected and stored for future batch analysis.  Blood plasma 
cytokines changes will be measured using commercially available ELISA kits (for TNFα, IL-4, IL-6, IL-8 and IL-10), 
which is the most validated and widely used method for this purpose. Other plasma-based measures of inflammation, 
including the blood CRP level and ESR will also be assessed. 
 
Histological analysis of inflammation : Patients in clinical remission from UC still frequently have histologic features of 
inflammation, which correlate with endoscopic appearance72.  We will utilize the same procedures for tissue acquisition, 
f
ixation and pathologic examination as described previously72. Six of the seven colon biopsies will be embedded for 
hi
stology and immunohistochemistry. Histologic sections will be stained with H&E and the severity of histologic 
inflammation will be evaluated using the Geboes grading system25, 72. 
 
Immunuhistochemical analysis of inflammation : Six of the seven colon biopsies will be embedded for histology and IHC.  
IHC has the advantage of allowing identification of the cells being probed but has the disadvantage of being semi-
quantitative with regards to intensity and expression.  Colonic epithelial apoptosis and cell proliferation will be 
determined by cleaved caspase-3 and Ki-67, respectively.  Caspase-3 and Ki-67 will be assessed using IHC since the 
percentage of positive cells is the gold standard for reporting these results.  Cleaved caspase-3 and Ki-67 are robust, well-
validated measures of these parameters.  TNFα, COX-2, and NF-κB will also be assessed by IHC.  For this, we will use 
computer-aided quantitation to improve the robustness of expression analysis. 
 
DNA methylation: One of the seven colon biopsies will be used for DNA methylation analysis. DNA methylation has 
been reported to be correlated with the development of colitis-associated cancer.  It has been reported that the methylation 
status of selective genes (SFRP1, TCERG1L, FBN2 and TFPI2) could be used as a risk marker for colon cancer in UC 
patients49.  Methylation analysis will be performed using the qMSP strategy, as previously described29.  The current study 
provides an opportunity to validate these associations, potentially leading to a means to identify high risk individuals with 
UC for progression towards colon cancer. 
 
Blood Berberine concentration measurement : Berberine concentrations in the research blood samples wi ll be analyzed 
using high-performance liquid chromatography /mass spectrometry (HPLC/MS). The following factors should be used to 
assess assay performance in human plasma  matrices:  selectivity, linearity, precision, accuracy, recovery and stability, 
following the FDA’s Guidance for Industry: Bioanalytical Method Validation [U.S. Department of Health and Human 
Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary 
Medicine (CVM), May 2001.] The Phase I Clinical Trials Center of Xijing hospital has successfully utilized HPLC/MS 
method for plasma drug concentration in their previous trial.  
 
Blood Count and Blood Chemistry:  Blood will also undergo standard clinical testing for complete blood count and blood 
chemistry to evaluate for end organ function.  
 
9.2 Comparable Methods  
 
Proposed methods represent standard technology for chemoprevention trials in the colon. 
 
 
10. SPECIMEN MANAGEMENT  
 
10.1Laboratories  
 
1. Dr. Aidong Wen’s laboratory at Xijing Hospital will be responsible for measuring the plasma Berberine 
concentrations. 
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
18 2. Clinical laboratory at Xijing Hospital will be responsible for the blood count and blood chemistry analyses as well as 
the ELISA assays. 
 
3. Dr. Zengshan Li’s laboratory will be responsible for the fixing, embedding, and sectioning of the biopsy samples and 
pathology review at Xijing Hospital. Tissue sections will be evaluated at both Pathologic Department of Xijing 
hospital and Pathology Core Facility (PCF) of Northwestern University.   
 
4. Dr. Guang- Yu Yang’s laboratory (PCF) will be responsible for the pathology review at Northwestern University. Dr. 
Li Xu will be responsible for shipping tissue sections to Dr. Yang at Pathology Core of Northwestern University, 
upon the approval of the Chinese government. Dr. Yang will be blinded to the nature of the sample and asked to 
review quantitation of expression by direct counts.  
 
5. Dr. Kaichun Wu’s laboratory will be responsible for the tissue sample DNA methylation analysis. 
 
10.2 Collec tion and Handling Procedures  
 
1. Blood for laboratory tests and research 
 
a. Blood (for cytokine levels; 4 ml)  
 
i. Pre-visit – The night before the scheduled visit, the participant should fast after midnight. 
 
ii. Collection -  The clinical laboratory will provide specimen collection kits with all sample 
collection, labeling and packaging information.  4 ml of research blood will be collected in a red-
top tubes for ELISA at the screening visit (before first dose) and at the 3 month visit.  The 
participant should be fasting. 
 
iii. Transportation - Blood samples will be transported to Xijing Hospital’s Clinical Laboratory at 
room temperature. All samples will be logged in the lab logbook with the times of arrival to the 
lab. 
 
iv. Labeling of specimen  – Samples will be de-identified through established SOPs. All samples will 
be labeled with the patient’s first initial of their last name followed by a number corresponding to 
their patient identification number assigned at the time of entry into the database (by research 
coordinator).  
 
v. Tracking of specimens  – The patient ID number will be used to link information on the database 
to clinical data.   
 
vi. Processing - The blood samples will be spun down (2500 rpm for 10 min) and separated 
immediately upon arrival . Serum for cytokine detection will be stored at −20 ˚C until analysis. 
 
vii. Archival - Unused serum samples will be stored at -20 ˚C for archival.   
 
b. Blood (for Berberine Concentration; 5 ml)  
 
i. Pre-visit – The night before the scheduled visit, the participant should fast after midnight. 
 
ii. Collection -  The clinical laboratory will provide specimen collection kits with all sample 
collection, labeling and packaging information.  5 ml of research blood will be collected in a 
purple-top EDTA tube for drug concentration measurement at the screening visit (before first 
dose) and at the 3 month visit. The participant should be fasting. 
 
iii. Labeling of specimen  – Samples will be de-identified through established SOPs. All samples will 
be labeled with the patient’s first initial of their last name followed by a number corresponding to 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
19 t
heir patient identification number assigned at the time of entry into the database (by research 
coordinator).  
 
iv. Tracking of specimens  – The patient ID number will be used to link information on the database 
to clinical data.   
 
v. Transportation - Blood samples will be transported to Dr. Zengshan Li’s laboratory at room 
temperature. 
 
vi. Processing - Plasma samples will be separated and spun down (4000 rpm for 3 min) immediately 
upon arrival.  Samples will be aliquoted and stored at −80˚C until analysis. 
 
vii. Archival  – After analysis is complete, samples will be stored at −80˚C for archival. 
 
2. Rectal Biopsies (7) 
 
a. Colorectal Biopsy (for histology – IHC and H&E ; 6 biopsies)  
 
i. Pre-visit – On the day prior to the exam, the patient will begin a clear liquid diet starting at lunch. 
On the scheduled day, the patients will come to the endoscopy unit fasting after midnight.  
 
ii. Collection -  The clinical laboratory will provide specimen collection kits with all sample 
collection, labeling and packaging information.  7 rectal biopsies will be collected.  6 of the 
biopsies will be placed in formalin immediately.  
 
iii. Labeling of specimen  – Samples will be de-identified through established SOPs. All samples will 
be labeled with the patient’s first initial of their last name followed by a number corresponding to 
their patient identification number assigned at the time of entry into the database (by research 
coordinator).  
 
iv. Tracking of specimens  – The patient ID number will be used to link information on the database 
to clinical data. The number of biopsies for each container will be recorded for each procedure.  
The pathology readings and all research data regarding biopsies will be entered into this database.  
 
v. Transportation - The biopsies in formalin will be transported (at room temperature) on the same 
day as the biopsy procedure to Dr. Zengshan Li’s laboratory in the pathology department at 
Xijing Hospital for histology processing.  
 
vi. Temperature storage requirements – Samples in formalin will be stored at room temperature until 
adequate fixation is achieved (i.e., overnight).  
vii. Processing – After adequate fixation, tissues will be transferred through baths of progressively 
more concentrated ethanol to remove the water, and followed by a hydrophobic clearing agent 
(such as xylene) to remove the alcohol, and finally molten paraffin wax, the infiltration agent, 
which replaces the xylene. Tissues will then be embedded in paraffin wax.   5 um section cuts 
will be used for H&E and IHC. 
 
viii. H&E Staining -  For H&E staining, briefly,  slides  will be dried at 65 ℃ for 1-2 hours, pass 
through xylene to remove paraffin, and pass through baths of progressively less concentrated 
ethanol to remove xylene and rinsed in tap water to remove ethanol.  Cellular nucleus will be 
stained with Hematoxylin for 10 minutes, rinsed through tap water to remove Hematoxylin, 
acided with 0.1% HCl, and stained with Eosin.    
 
ix. IHC -  Antigen retrieval of formalin fixed paraffin sections is performed using Target retrieval 
solution (Dako, Carpinteria, CA) with a decloaking chamber (Biocare medical, Concord CA).  
Sections are stained for Ki67 clone TEC-3 (1:400, Dako), active caspase 3 (San Diego, CA) or 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
20 ant
i- TNFα, anti- COX -2, and anti- NF-κB.  After overnight incubation of primary antibody, 
sections were incubated with anti-rabbit or mouse HRP labeled polymer (Dako) or anti-rat 
VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA).  
 
x. Archival  – Tissues in paraffin blocks will be stored at room temperature until processed and then 
archived at room temperature for future studies.  In some cases, it may be necessary to go back 
into a block to cut more slides.  Thus, all blocks will be catalogued and preserved until they have 
been exhausted or until such time they are no longer useful.  
 
xi. Shipping - For slides shipping to Northwestern, slides will be cut 1 day before shipping and 
shipped through FedEx at room temperature . Upon arrival, slides will be stored at room 
temperature and used for IHC and H&E staining.  
 
b. Colorectal Biopsy (for DNA methylation ; 1 biopsy)  
 
i. Pre-visit – On the day prior to the exam, the patient will begin a clear liquid diet starting at lunch. 
On the scheduled day, the patients will come to the endoscopy unit fasting after midnight.  
 
ii. Collection -  The clinical laboratory will provide specimen collection kits with all sample 
collection, labeling and packaging information.  7 rectal biopsies will be collected.  1 of the 
biopsies should be flash frozen in liquid nitrogen.  
 
iii. Labeling of specimen  – Samples will be de-identified through established SOPs. All samples will 
be labeled with the patient’s first initial of their last name followed by a number corresponding to 
their patient identification number assigned at the time of entry into the database (by research 
coordinator).  
 
iv. Tracking of specimens  – The patient ID number will be used to link information on the database 
to clinical data. The number of biopsies for each container will be recorded for each procedure.  
The pathology readings and all research data regarding biopsies will be entered into this database.  
 
v. Transportation - The biopsy that w as flash frozen should be transported to Dr. Kaichun Wu’s 
laboratory on dry ice. 
 
vi. Temperature storage requirements  – T he frozen biopsy sample will be stored in a -80˚C freezer 
until processing.  
 
vii. Processing – Methylation analysis will be performed using the qMSP strategy, as previously 
described1,2.  DNA will be extracted following a standard phenol-chloroform extraction protocol. 
B
isulfite modification of DNA will be performed using the EZ DNA Methylation™ Kit (Zymo 
Research) according to the manufacturer’s instructions. Methylation-specific PCR was carried out 
in a 25-μl reaction containing 10X MSP buffer, 10 mM dNTPs, 10 pmol of each of the 
methylated or unmethylated primers, 1 unit of JumpStart™ REDTaq® DNA polymerase (Sigma) 
and 4 μl of bisulfite-treated DNA. Amplification cycles were as follows: one cycle at 95°C for 5 
min followed by 35 cycles of 95°C for 30 sec, annealing temp for 30 sec, 72°C for 30 sec and a 
final extension step at 72°C for 5 min.  
 
viii. Archival  – Samples will be stored until processed and then archived for future studies.  Samples 
will be catalogued and preserved (-80˚ C) until they have been exhausted or until such time they 
ar
e no longer useful.  
 
10.3 Shipping Instructions 
 
D
r. Li Xu will be responsible for shipping tissue sections to Dr. Guang -Yu Yang at Pat hology Core of Northwestern 
University  for additional histological review  upon the approval of the Chinese government.  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
21  
Sam
ples should be shipped at the end of the study. 
 
C
oordinate delivery with Dr. Guang- Yu Yang ( g-yang@northwestern.edu ) and send FedEx tracking number to ensure 
onsite tracking.   
 
Note: Contact ncpc@northwestern.edu  (312-695-1408) prior to sending samples to determine the best day to ship. 
 
Northwestern will provide account number for samples shipments.  
 
All samples will be shipped in compliance with the International Air Transport Association (IATA) Dangerous Goods 
Regulations. 
 
Samples should be shipped to the following address: 
 
     Dr. Guang- Yu Yang 
 
    Northwestern University 
     Department of Pathology 
  Ward 6-116  
     303 E. Chicago Avenue    
    Chicago, IL   60611  
  
Phone: (312) 503-0645  
  Fax: (312) 503-0647    
  Email: g-yang@northwestern.edu 
 
Upon arrival, samples should be stored at room temperature. 
 
10.4 Tissue Banking  
 
B
iologic specimens collected during the conduct of each clinical trial that are not used during the course of the study will 
be considered deliverables under the contract and thus the property of the NCI. At study completion, NCI reserves the 
option to either retain or relinquish ownership of the unused biologic specimens. If NCI retains ownership of specimens, 
the Contractor shall collect, verify and transfer the requested biologic specimens from the site to a NCI-specified 
repository or laboratory at NCI’s expense.   
 
 
11. REPORTING ADVERSE EVENTS  
 
DEFINITION: AE means any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug related. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally 
associated with participation in a study, whether or not related to that participation. This includes all deaths that occur 
while a participant is on a study.  
 
Please note that all abnormal clinical laboratory values that are determined to be of clinical significance based on a 
physician’s assessment are to be reported as AEs. Those labs determined to be of no clinical significance or of unknown 
clinical significance (per the physician’s assessment) should not be reported as AEs. Any lab value of unknown clinical 
significance should continue to be investigated/followed-up further for a final determination, if possible. 
 
A list of AEs that have occurred or might occur (Reported Adverse Events and Potential Risks) can be found in §6.2, 
Pharmaceutical Information, as well as the package insert.  
 
11.1 Adverse Events 
 
11.1.1
 Reportable AEs 
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
22 A
ll AEs that occur after the informed consent is signed and baseline assessments are completed must be recorded on the 
AE CR F (paper and/or electronic) whether or not related to study agent.  
 
11.1.2
 AE Data Elements: 
 
The following data elements are required for adverse event reporting. 
 AE verbatim term 
 System Organ Class (SOC) 
 Common Terminology Criteria for Adverse Events v4.0 (CTCAE) AE term 
 Event onset date and event ended date 
 Severity grade 
 Attribution to study agent (relatedness) 
 Whether or not the event was reported as a serious adverse event (SAE) 
 Whether or not the subject dropped due to the event 
 Outcome of the event 
 Report date  
 Action  
 
11.1.3  Severity of AEs 
   
Identify the AE using the CTCAE version 4.0. The CTCAE provides descriptive terminology and a grading scale for each 
adverse event listed. A copy of the CTCAE can be found at 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm  
 
AEs will be assessed according to the CTCAE grade associated with the AE term. AEs that do not have a corresponding 
CTCAE term will be assessed according to the general guidelines for grading used in the CTCAE v4.0. as stated below.  
 
 
CTCAE v4.0 general severity guidelines:  
 
Grade  Severity  Description  
1 Mild  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
2 Moderate  Moderate;  minimal, local or noninvasive intervention indicated;  
limiting age -appropriate instrumental activities of daily living (ADL)*.  
3 Severe  Severe or medically significant but not immediately life -threatening;  
hospitalization or prolongation of hospitalizati on indicated; disabling; limiting self -
care ADL**.  
4 Life-threatening  Life-threatening consequences; urgent intervention indicated.  
5 Fatal  Death related to AE.  
   
ADL  
 
*Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, 
etc. 
 
**Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not 
bedridden. 
 
11.1.4 Assessment of relationship of AE to treatment 
  
The possibility that the adverse event is related to study agent will be classified as one of the following: not related, 
unlikely, possible, probable, definite. 
  
11.1.5 Follow-up of AEs 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
23  
A
ll AEs, including lab abnormalities that in the opinion of the investigator are clinically significant, will be followed 
according to good medical practices and documented as such. 
 
11.2 Serious Adverse Events  
 
11.2.1
 DEFINITION: The only clinical site is in China.  The China Food and Drug Administration (formerly the State 
Food and Drug Administration) SFDA Order No. 3, Article 68, Sep. 1 2003 defines SAEs as those events which occur 
duirng a clinical trial and  which include any of the following criteria: 
 Inpatient hospitalization 
 Prolongation of  hospitalization 
 Disability/incapacity 
 Effect on work capability 
 Life threatening 
 Death 
 Congenital anomaly 
 
11.2.2 Reporting SAEs to DCP 
 
11.2.2.1      The Lead Organization and all Participating Organizations will report SAEs on the DCP SAE form found at 
http://prevention.cancer.gov/files/clinical-trials/SAE_form.doc . 
 
11.2.2.2       Contact the DCP Medical Monitor by phone or email within 24 hours of knowledge of the event.  
 
DCP Medical /Scientific Monitor  
Luz Maria Rodriguez, MD, FACS 
NCI/Division of Cancer Prevention  
9609 Medical Center Dr 
Rm 5E-228 
Telephone (240) 276-7039  
Fax (240) 276-7848  
Email: rodrigul@mail.nih.gov  
Include the following information when calling the Medical Monitor: 
 Date and time of the SAE 
 Date and time of the SAE report 
 Name of reporter 
 Call back phone number 
 Affiliation/Institution conducting the study 
 DCP protocol number 
 Title of protocol 
 Description of the SAE, including attribution to drug and expectedness 
 
11.2.2.3      The Lead Organization and all Participating Organizations will FAX or email written SAE reports to the DCP 
Medical Monitor within 48 hours of learning of the event using the paper SAE form. The written SAE reports will also be 
faxed (650-691-4410) or emailed ( safety@ccsainc.com ) to DCP’s Regulatory Contractor, CCS Associates (phone: 650-
691-4400).   The written SAE reports will also be faxed (312-695-1352) or emailed ( ncpc@northwestern.edu ) to the Lead 
Organization Research Project Manager (phone: 312-695-0562) if sent by a Participating Organization.  Because certified 
translations cannot be obtained in time, two copies of SAE reports will be completed: one in Chinese, and one in English.  
All SAE reports completed in Chinese will be translated into English then compared to the original English version to 
ensure accuracy. 
 
11.2.2.4    The site-PI will determine which S AEs require submission to the China Food and Drug Administration.   
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
24 11.2.2.5
    The Lead Organization and all Participating Organizations will comply with applicable regulatory requirements 
related to reporting SAEs to the IRB/IEC.  The only clinical site for this study is in China .  SAE’s will be reported to 
Northwestern University’s IRB, Xijing Hospital’s Ethics Committee, and to the CFDA in accordance with their 
respective reporting requirements.  A copy of all SAE reports sent to CFDA will be provided to DCP and translated 
into English. 
 
11.2.3 Follow-up of SAE 
 
Site staff should send follow-up reports as requested when additional information is available.  Additional information 
should be entered on the DCP SAE form in the appropriate format.  Follow-up information should be sent to DCP and 
Lead Organization as soon as possible according to the DCP Serious Adverse Event Reporting Procedures and Guidelines.  
SAEs will be followed per protocol for 30 days after treatment completion or until all side effects have been resolved, 
whichever occurs later.   As with the initial SAE report, follow-up SAE reports will be completed in Chinese and English.  
All follow-up SAE reports completed in Chinese will be translated into English then compared to the original English 
version to ensure accuracy. 
 
 
12. STUDY MONITORING 
 
12.1 Data Management 
 
See Append
ix E, Data Management Plan.   
 
12.2 Case Report Forms 
 
See Appendix E, Data Management Plan. 
 
12.3 Source Documents 
 
All source documents will be collected and stored at the study site.  Any data recorded directly on CRFs that constitute no 
prior written or electronic record of data, will be specifically identified as source data.  
 
12.4 Data and Safety Monitoring Plan 
 
A
 comprehensive Data Safety and Monitoring Plan has been submitted by Northwestern University, approved by DCP, 
and is on file there. 
 
The Participating Organization will be monitored by the Northwestern Cancer Prevention Consortium (NCPC) Research 
Project Manager.  Given the difficulty of planning participant accrual and travel to China, the first monitoring visit will 
occur approximately after the fifth participant enrolls, with subsequent annual visits.  The NCPC will employ an 
English/Chinese translator to assist with verifying Chinese source documents.    
 
12.5 Sponsor or Chi na Food and Drug Administration  Monitoring  
 
The NCI, DCP (or their designee), pharmaceutical collaborator (or their designee), or CFDA may monitor/audit various 
aspects of the study. These monitors will be given access to facilities, databases, supplies and records to review and verify  
data pertinent to the study.  
 
12.6 Record Retention 
 
Clinical records for all participants, including CRFs, all source documentation (containing evidence to study eligibility, 
history and physical findings, laboratory data, results of consultations, etc.), as well as IRB/Ethics Committee  records and 
ot
her regulatory documentation , will be retained by th e  Investigator in a secure storage facility in compliance with 
HIPAAOffice of Human Research Protections (OHRP), CFDA regulations and guidances, and NCI/DCP requirements, 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
25 unl
ess the standard at the site is more stringent. The records for all studies performed in China will be retained for, at 
minimum, five years after the completion of the research.  For NCI/DCP, records will be retained for at least three years 
after the completion of the research. NCI will be notified prior to the planned destruction of a ny materials. The records 
should be accessible for inspection and copying by authorized persons of the China Food and Drug Administration. 
Because this  study is done outside of the United States, applicable regulatory requirements for the China  study also app ly. 
 
12.7 Cooperative Research and Development Agreement (CRADA)/Clinical Trials Agreement (CTA) 
 
A
ll study agents are to be purchased commercially.  No CRADA or CTA is applicable to this study.   
 
13. STATISTICAL CONSIDERATIONS 
 
13.1 Study Design/Description 
 
T
his is a Phase I, placebo controlled, safety and tolerability study.  Randomization is double-blinded. The primary 
endpoint is clinical safety and tolerability.  Secondary endpoints are plasma- and tissue-based measures of inflammation, 
clinical efficacy, and compliance (via blood drug concentrations). 
 
13.2 Randomization/Stratification  
 
Pat
ients will be randomized by the study statistician.  12 subjects will receive treatment with Berberine and 4 subjects will 
receive the placebo, in a randomized, double-blinded manner and stratified by gender.  Two additional participants are 
anticipated to be accrued (for a total of 18 subjects) to account for an anticipated dropout rate of 10%.  In order to keep the 
numbers in either treatment group as planned, dropouts in either treatment group will be replaced by subjects assigned to 
that same treatment and gender group.  The ratio of men to women in each treatment group (Berberine/placebo) will be 
1:1.  The randomization list will be provided by the study statistician to the Investigational pharmacist at Xijing Hospital. 
Only the Northwestern CRO Quality Assurance Monitors, statistician, and the research pharmacist at Xijing Hospital will 
know which patient is receiving which treatment. 
 
13.3 Ac crual and Feasibility 
 
In a typical month, there are 3-4 subjects identified who would qualify for chemoprevention trials, and about 1/3 of these 
subjects are agreeable to consider entering trials.  We plan to enroll a total of 16- 18 subjects (1 treatment arm with 12 
sub
jects and one placebo group with 4 subjects, with 2 additional subjects to account for anticipated attrition; dropouts in 
either group will be replaced by subjects assigned to that same treatment and gender group).  We anticipate this taking 
about 6-12 months to complete.  We also have subjects who participated in prior trials who have provided consent to be 
contacted for future studies. 
 
13.4 Primary Objective, Endpoint(s), Analysis Plan 
 
Primary Objective:  To determine the safety of Berberine administered to patients with UC in clinical remission while 
receiving maintenance therapy with Mesalamine.   
 
Endpoints:  The primary objective will be evaluated by determining whether given subject experiences grade 2 systemic 
toxicity or not.  Upon unblinding the placebo and treatment assignments, relevant counts and rates will be evaluated and 
reported.  Specifically, in addition to assessing clinical toxicity, we will collect tissue and blood samples from recruited 
participants at the beginning of the trial and at the end of Berberine administration (three months later) and evaluate organ 
toxicity by standard clinical chemistry tests. Also, we will read tissue samples in China and the US.  Finally, we will 
observe and record symptoms such as fever, fatigue, weight loss, appetite, stool frequency, bloody stool and other upper 
and lower gastrointestinal tract symptoms in participants. 
 
Analysis: We plan to recruit 12 treatment and 4 placebo subjects for a total of 16 evaluable subjects. With potential 
dropout of 2 subjects we plan to recruit a total of 18 subjects.  Dropouts in either treatment group will be replaced by 
subjects assigned to that same treatment and gender group.  We do not expect to see any toxicity in either group of 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
26 pa
tients; in fact we believe the underlying toxicity rate is the same in both groups. With no observed toxicities, we will be 
able to establish an approximate 95% upper bound on Prob(Tox) as the “Rule of Three”: 3/(n+1) or 3/17 = 0.18 for both 
groups and  3/13 = 0.23 for the treatment group43.  Other statistical analysis will consist of providing descriptive statistics 
(mean, SD, max, min) on patient characteristics and on toxicity rates; in case no events occur, appropriate methods will be 
used, such as the Rule of Three above for upper confidence bound, continuity correction or exact confidence bounds for 
two-sided intervals. 
 
13.5 Secondary Objectives, Endpoints, Analysis Plans 
 
Sec
ondary Objectives:  To determine the efficacy of Berberine and compliance of subjects. 
 
Endpoints and Analyses: 
 
 For plasma biomarkers, we will use descriptive statistics and graphical methods to present the evidence of 
possible correlations in outcomes of interest.  Box plots and confidence intervals will be used to assign proper 
mass weight to groups of observations.  “Before” and “after” intervention values and their difference will be 
compared with suitably chosen counterparts. 
 
 Colorectal tissue IHC biomarkers and DNA methylation status for SFRP1, TCERGIL, FBN2 and TFP12 will be 
measured twice, before and after the treatment, and their difference will be studied in relative to values in their 
respective control groups. The Ki-67 and cleaved caspase 3 outcomes will be the number of cells positive over 
total number. The TNFα, COX-2, and NF-κB immunohistochemistry will be done by quantitation through 
chromovision and will be expressed as % of control (placebo, pre-treatment).  The description and comparison of 
biomarkers and gene methylation status will be performed both with the view of Before – After possible change 
within each treatment group, as well as with the view of Treatment - Control groups for Before and for the After 
period.  Descriptive statistics and graphical methods will be performed to present the evidence of possible 
correlations in outcomes of interest. Tissue biomarkers will be measured in China and separately in the US. 
Comparisons of before and after treatment will be performed separately as a function of country, and then 
differences between countries will be compared.  This will be done with the purpose of gaining knowledge of the 
range of changes to plan future studies in these markers. 
 
 Blood drug concentration will be measured before and after 3 months treatment. Comparisons of before and after 
treatment will be performed.   
 
13.6 Reporting and Exclusions 
 
C
ompliance will be formally assessed by clinical visit and pill counts each month, and by measuring blood drug 
concentrations at the end of the study.  Patients will be considered compliant if they have taken 80% of their study agent 
doses as directed.  During the first month of study, patients will be counseled regarding the importance of taking all doses, 
but will not be removed from the study for missing doses, unless 10 consecutive days are missed.  Patients who are found 
to be non-compliant at the monthly assessments will be kept in the study; their information will be used in the final ‘intent 
to treat’ analysis, which will contain all randomized patients. 
 
We expect that of 18 recruited participants, all will have complete data; it is possible that up to 10% of participants drop 
out.  Participants will not be replaced.  Analysis will be based upon complete data.   
 
13.7 Evaluation of Toxicity  
 
A
ll participants will be evaluated for toxicity from the time of their first dose of Berberine through day 120 
(corresponding to one month after completing the 90 day treatment period). 
 
13.8 Evaluation of Response 
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
27 A
ll participants included in the study will be assessed for response to intervention, even if there are major protocol 
deviations or if they are ineligible. All of the participants who met the eligibility criteria (with the possible exception of 
those who did not receive study agent) will be included in the main analysis. All conclusions regarding efficacy will be 
based on all eligible participants.  Refer to section 13.5 for information on evaluation of response. 
 
13.9 Interim Analysis 
 
T
oxicity will be evaluated continuously as outlined above. 
 
13.10 Ancillary Studies  
 
N/A 
 
 
14. ETHICAL AND REGULATORY CONSIDERATIONS 
 
14.1 Form FDA 1572 
 
Pri
or to initiating this study, the Protocol Lead Investigator at the Lead or Participating Organization(s) will provide a 
sig
ned Form FDA 1572 stating that the study will be conducted in compliance with regulations for clinical investigations 
and listing the investigators, at each site that will participate in the protocol. All personnel directly involved in the 
performance of procedures required by the protocol and the collection of data should be listed on Form FDA 1572. 
 
14.2 Other Required Documents 
 
14.2.1
 Signed and dated current (within two years) CV or biosketch (translated into English, if necessary) for all study 
personnel listed on the Form FDA 1572 and Delegation of Tasks form for the Lead Organization and all Participating 
Organizations.  
 
14.2.2 Current medical licenses (where applicable, and translated into English, if necessary) for all study personnel listed 
on Form FDA 1572 and Delegation of Tasks form for the Lead Organization and all Participating Organizations. 
 
14.2.3  Lab certification ( e.g., CLIA, CAP, and translated into English, if necessary ) and lab normal ranges (translated 
into English, if necessary) for all labs listed on Form FDA 1572 for the Lead Organization and all Participating 
Organizations. 
 
14.2.4  Documentation of training in “Protection of Human Research Subjects” for all study personnel listed on the FDA 
Form 1572 and Delegation of Tasks form for the Lead Organization and all Participating Organizations will be obtained.  
For pe
rsonnel in China, each certificate of human subjects' protection training will be obtained but will not be translated 
into English.  Instead, we will obtain a letter, in English, on Xijing Hospital letter head and signed by the Ethics 
Committee, listing the names of the study personnel who have completed this training. 
 
14.2.5  Documentation of Federalwide Assurance (FWA) number for the Lead Organization and all Participating 
Organizations. 
 
14.2.6  Signed Package Insert acknowledgement form 
 
14.2.7  Delegation of Tasks form for the Lead Organization and all Participating Organizations signed by the Principal 
Investigator for each site and initialed by all study personnel listed on the form 
 
14.2.8  Signed and dated NCI, DCP Financial Disclosure Form for all study personnel listed on Form FDA 1572 for the 
Lead Organization and all Participating Organizations 
 
14.3 Institutional Review Board Approval 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
28  
Pri
or to initiating the study and receiving agent, the Investigators at the Lead Organization and the Participating 
Organization(s) must obtain written approval to conduct the study from the appropriate IRB/Ethics Committee.  Should 
changes to the study become necessary, protocol amendments will be submitted to the DCP PIO according to DCP 
Amendment Guidelines. The DCP-approved amended protocol must be approved by the IRB/Ethics Committee prior to 
implementation. Ethics Committee approvals and Informed Consent documents in Chinese will be translated into English 
as part of the site essential regulatory documents. 
 
14.4 Informed Consent 
 
A
ll potential study participants will be given a copy of the IRB/Ethics Committee-approved Informed Consent to review. 
The investigator will explain all aspects of the study in lay language and answer all questions regarding the study. If the 
participant decides to participate in the study, he/she will be asked to sign and date the Informed Consent document. The 
study agent(s) will not be released to a participant who has not signed the Informed Consent document. Subjects who 
refuse to participate or who withdraw from the study will be treated without prejudice. 
 
Participants must be provided the option to allow the use of blood samples, other body fluids, and tissues obtained during 
tes
ting, operative procedures, or other standard medical practices for further research purposes. If applicable, statement of 
this option may be included within the informed consent document or may be provided as an addendum to the consent. A 
Model Consent Form for Use of Tissue for Research is available through a link in the DCP website. 
 
Prior to study initiation, the informed consent document must be reviewed and approved by NCI, DCP, the Consortium 
Lead Organization, and the IRB at each Organization at which the protocol will be implemented. Any subsequent changes 
to the informed consent must be approved by NCI, DCP, the Consortium Lead Organization’s IRB, and then submitted to 
each organization’s IRB for approval prior to initiation. Ethics Committee approvals and Informed Consent documents in 
Chinese will be translated into English as part of the site essential regulatory documents. 
 
14.5 Submission of Regulatory Documents 
 
All regulatory documents are collected by the Consortia Lead Organization and reviewed for completeness and accuracy. 
Once the Consortia Lead Organization has received complete and accurate documents from a participating organization, 
the Consortium Lead Organization will forward the regulatory documents to the DCP Regulatory Contractor: 
 
 Paper Document/CD-ROM Submissions: 
 Regulatory Affairs Department 
 CCS Associates 
 2001 Gateway PL, Suite 350W 
 San Jose, CA 95110 
 
 E-mail Submissions: 
 regulatory@ccsainc.com  
 
Regulatory documents that do not require an original signature may be sent electronically to the Consortium Lead 
Organization for review at ncpc@northwestern.edu , which will then be electronically forwarded to the DCP Regulatory 
Contractor. 
 
14.6 Other 
 
This trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and the applicable regulatory 
requirements. 
 
 
15. FINANCING, EXPENSES, AND/OR INSURANCE 
 
All research related costs associated with participating in this study will be paid for, and will not be the responsibility of 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
29 t
he participant.   
 
Participants will not get monetary remuneration, but the cost of study-specific biopsies and exams, tests, and any other 
procedures will be paid for by the study. Special outpatient visiting time will be arranged for their visit.  
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
30 R
EFERENCES 
 
 
1 S. M. Adams, and P. H. Bornemann, 'Ulcerative Colitis', Am Fam Physician, 87 (2013), 699-705. 
2 K. V. Anis, N. V. Rajeshkumar, and R. Kuttan, 'Inhibition of Chemical Carcinogenesis by Berberine in Rats and 
Mi
ce', J Pharm Pharmacol, 53 (2001), 763-8. 
3 L. Beaugerie, M. Svrcek, P. Seksik, A. M. Bouvier, T. Simon, M. Allez, H. Brixi, J. M. Gornet, R. Altwegg, P. 
B
eau, B. Duclos, A. Bourreille, J. Faivre, L. Peyrin-Biroulet, J. F. Flejou, F. Carrat, and Cesame Study Group, 
'Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients with 
Inflammatory Bowel Disease', Gastroenterology, 145 (2013), 166-75 e8. 
4 R. Bergman, and M. Parkes, 'Systematic Review: The Use of Mesalazine in Inflammatory Bowel Disease', 
A
liment Pharmacol Ther, 23 (2006), 841-55. 
5 M. M. Bertagnolli, 'Chemoprevention of Colorectal Cancer with Cyclooxygenase-2 Inhibitors: Two Steps 
Forwar
d, One Step Back', Lancet Oncol, 8 (2007), 439-43. 
6 T.C . Birdsall, and G.S. Kelly, 'Berberine: Therapeutic Potential of an Alkaloid Found in Several Medicinal 
Plants', Altern. Med. Rev., 2 (1997), 94-103. 
7 H. Cao, S. Song, H. Zhang, Y. Zhang, R. Qu, B. Yang, Y. Jing, T. Hu, F. Yan, and B. Wang, 'Chemopreventive 
Eff
ects of Berberine on Intestinal Tumor Development in Apcmin/+ Mice', BMC Gastroenterol, 13 (2013), 163. 
8 M. Cao, P. Wang, C. Sun, W. He, and F. Wang, 'Amelioration of Ifn-Gamma and Tnf-Alpha-Induced Intestinal 
Epit
helial Barrier Dysfunction by Berberine Via Suppression of Mlck-Mlc Phosphorylation Signaling Pathway', 
PLoS One, 8 (2013), e61944. 
9 W. Chen, R. Zheng, S. Zhang, P. Zhao, G. Li, L. Wu, and J. He, 'The Incidences and Mortalities of Major Cancers 
i
n China, 2009', Chin J Cancer, 32 (2013), 106-12. 
10 W. Chen, R. Zheng, S. Zhang, P. Zhao, G. Li, L. Wu, J. He, 'Report of Incidence and Mortality in China Cancer 
Registries, 2009', Chin J Cancer Res, 25 (2013), 10-21. 
11 K. N. Chidambara Murthy, G. K. Jayaprakasha, and B. S. Patil, 'The Natural Alkaloid Berberine Targets Multiple 
Pathways to Induce Cell Death in Cultured Human Colon Cancer Cells', Eur J Pharmacol, 688 (2012), 14-21. 
12 M. L. Clapper, H. S. Cooper, and W. C. Chang, 'Dextran Sulfate Sodium-Induced Colitis-Associated Neoplasia: 
A Promising Model for the Development of Chemopreventive Interventions', Acta Pharmacol Sin, 28 (2007), 
1450-9. 
13 R. M. Cooney, B. F. Warren, D. G. Altman, M. T. Abreu, and S. P. Travis, 'Outcome Measurement in Clinical 
Trials for Ulcerative Colitis: Towards Standardisation', Trials, 8 (2007), 17. 
14 J. Cosnes, C. Gower-Rousseau, P. Seksik, and A. Cortot, 'Epidemiology and Natural History of Inflammatory 
Bowel Diseases', Gastroenterology, 140 (2011), 1785-94. 
15 M. De Robertis, E. Massi, M. L. Poeta, S. Carotti, S. Morini, L. Cecchetelli, E. Signori, and V. M. Fazio, 'The 
Aom/Dss Murine Model for the Study of Colon Carcinogenesis: From Pathways to Diagnosis and Therapy 
Studies', J Carcinog, 10 (2011), 9. 
16 V. K. Denmark, and L. Mayer, 'Current Status of Monoclonal Antibody Therapy for the Treatment of 
Inflammatory Bowel Disease: An Update', Expert Rev Clin Immunol, 9 (2013), 77-92. 
17 A. B. Desai, K. M. Shah, and D. M. Shah, 'Berberine in Treatment of Diarrhoea', Indian Pediatr, 8 (1971), 462-5. 
18 B. K. Edwards, A. M. Noone, A. B. Mariotto, E. P. Simard, F. P. Boscoe, S. J. Henley, A. Jemal, H. Cho, R. N. 
Anderson, B. A. Kohler, C. R. Eheman, and E. M. Ward, 'Annual Report to the Nation on the Status of Cancer, 
1975-2010, Featuring Prevalence of Comorbidity and Impact on Survival among Persons with Lung, Colorectal, 
Breast, or Prostate Cancer', Cancer (2013). 
19 R. N. Fedorak, and M. Field, 'Antidiarrheal Therapy. Prospects for New Agents', Dig Dis Sci, 32 (1987), 195-205. 
20 A. C. Ford, J. P. Achkar, K. J. Khan, S. V. Kane, N. J. Talley, J. K. Marshall, and P. Moayyedi, 'Efficacy of 5-
Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis', Am J Gastroenterol, 106 (2011), 
601-16. 
21 A. C. Ford, K. J. Khan, J. P. Achkar, and P. Moayyedi, 'Efficacy of Oral Vs. Topical, or Combined Oral and 
Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis', Am J Gastroenterol, 
107 (2012), 167-76; author reply 77. 
22 L. Fu, W. Chen, W. Guo, J. Wang, Y. Tian, D. Shi, X. Zhang, H. Qiu, X. Xiao, T. Kang, W. Huang, S. Wang, and 
W. Deng, 'Berberine Targets Ap-2/Htert, Nf-Kappab/Cox-2, Hif-1alpha/Vegf and Cytochrome-C/Caspase 
Signaling to Suppress Human Cancer Cell Growth', PLoS One, 8 (2013), e69240. 
23 K. Fukuda, Y. Hibiya, M. Mutoh, M. Koshiji, S. Akao, and H. Fujiwara, 'Inhibition by Berberine of 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
31 C
yclooxygenase-2 Transcriptional Activity in Human Colon Cancer Cells', J Ethnopharmacol, 66 (1999), 227-33. 
24 K. Fukuda, Y. Hibiya, M. Mutoh, M. Koshiji, S. Akao, H. Fujiwara, 'Inhibition of Activator Protein 1 Activity by 
Berberine in Human Hepatoma Cells', Planta Med, 65 (1999), 381-3. 
25 K. Geboes, R. Riddell, A. Ost, B. Jensfelt, T. Persson, and R. Lofberg, 'A Reproducible Grading Scale for 
Histological Assessment of Inflammation in Ulcerative Colitis', Gut, 47 (2000), 404-9. 
26 S. C. Gupta, J. H. Kim, S. Prasad, and B. B. Aggarwal, 'Regulation of Survival, Proliferation, Invasion, 
Angiogenesis, and Metastasis of Tumor Cells through Modulation of Inflammatory Pathways by Nutraceuticals', 
Cancer Metastasis Rev, 29 (2010), 405-34. 
27 T. P. Hamsa, and G. Kuttan, 'Antiangiogenic Activity of Berberine Is Mediated through the Downregulation of 
Hypoxia-Inducible Factor-1, Vegf, and Proinflammatory Mediators', Drug Chem Toxicol, 35 (2012), 57-70. 
28 K. Hemminki, X. Li, J. Sundquist, and K. Sundquist, 'Cancer Risks in Ulcerative Colitis Patients', Int J Cancer, 
123 (2008), 1417-21. 
29 
J. G. Herman, J. R. Graff, S. Myohanen, B. D. Nelkin, and S. B. Baylin, 'Methylation-Specific Pcr: A Novel Pcr 
Assay for Methylation Status of Cpg Islands', Proc Natl Acad Sci U S A, 93 (1996), 9821-6. 
30 L. J. Herrinton, L. Liu, T. R. Levin, J. E. Allison, J. D. Lewis, and F. Velayos, 'Incidence and Mortality of 
Colorectal Adenocarcinoma in Persons with Inflammatory Bowel Disease from 1998 to 2010', Gastroenterology, 
143 (2012), 382-9. 
31 T. Hong, Z. Yang, C. F. Lv, and Y. Zhang, 'Suppressive Effect of Berberine on Experimental Dextran Sulfate 
Sodium-Induced Colitis', Immunopharmacol Immunotoxicol, 34 (2012), 391-7. 
32 W. H. Hsu, Y. S. Hsieh, H. C. Kuo, C. Y. Teng, H. I. Huang, C. J. Wang, S. F. Yang, Y. S. Liou, and W. H. Kuo, 
'Berberine Induces Apoptosis in Sw620 Human Colonic Carcinoma Cells through Generation of Reactive Oxygen 
Species and Activation of Jnk/P38 Mapk and Fasl', Arch Toxicol, 81 (2007), 719-28. 
33 P. F. Hu, W. P. Chen, J. L. Tang, J. P. Bao, and L. D. Wu, 'Protective Effects of Berberine in an Experimental Rat 
Osteoarthritis Model', Phytother Res, 25 (2011), 878-85. 
34 Z. Hu, Q. Jiao, J. Ding, F. Liu, R. Liu, L. Shan, H. Zeng, J. Zhang, and W. Zhang, 'Berberine Induces Dendritic 
Cel
l Apoptosis and Has Therapeutic Potential for Rheumatoid Arthritis', Arthritis Rheum, 63 (2011), 949-59. 
35 W. Hua, L. Ding, Y. Chen, B. Gong, J. He, and G. Xu, 'Determination of Berberine in Human Plasma by Liquid 
Chromatography-Electrospray Ionization-Mass Spectrometry', J Pharm Biomed Anal, 44 (2007), 931-7. 
36 N. Iizuka, K. Miyamoto, K. Okita, A. Tangoku, H. Hayashi, S. Yosino, T. Abe, T. Morioka, S. Hazama, and M. 
Oka, 'Inhibitory Effect of Coptidis Rhizoma and Berberine on the Proliferation of Human Esophageal Cancer Cell 
Lines', Cancer Lett, 148 (2000), 19-25. 
37 M. Imanshahidi, and H. Hosseinzadeh, 'Pharmacological and Therapeutic Effects of Berberis Vulgaris and Its 
Active Constituent, Berberine', Phytother Res, 22 (2008), 999-1012. 
38 A. B. Jensen, M. Larsen, M. Gislum, M. V. Skriver, P. Jepsen, B. Norgaard, and H. T. Sorensen, 'Survival after 
Colorectal Cancer in Patients with Ulcerative Colitis: A Nationwide Population-Based Danish Study', Am J 
Gastroenterol, 101 (2006), 1283-7. 
39 H. W. Jeong, K. C. Hsu, J. W. Lee, M. Ham, J. Y. Huh, H. J. Shin, W. S. Kim, and J. B. Kim, 'Berberine 
Suppresses Proinflammatory Responses through Ampk Activation in Macrophages', Am J Physiol Endocrinol 
Metab, 296 (2009), E955-64. 
40 T. Jess, C. Rungoe, and L. Peyrin-Biroulet, 'Risk of Colorectal Cancer in Patients with Ulcerative Colitis: A Meta-
Analysis of Population-Based Cohort Studies', Clin Gastroenterol Hepatol, 10 (2012), 639-45. 
41 L. Jiang, B. Xia, J. Li, M. Ye, C. Deng, Y. Ding, H. Luo, H. Ren, X. Hou, H. Liu, H. Xu, H. Cheng, and H. Yang, 
'Risk Factors for Ulcerative Colitis in a Chinese Population: An Age-Matched and Sex-Matched Case-Control 
Study', J Clin Gastroenterol, 41 (2007), 280-4. 
42 
Q. Jiang, P. Liu, X. Wu, W. Liu, X. Shen, T. Lan, S. Xu, J. Peng, X. Xie, and H. Huang, 'Berberine Attenuates 
Lipopolysaccharide-Induced Extracelluar Matrix Accumulation and Inflammation in Rat Mesangial Cells: 
Involvement of Nf-Kappab Signaling Pathway', Mol Cell Endocrinol, 331 (2011), 34-40. 
43 B. Jovanovic, Rule of Three: Binomial Confidence Intervals When No Responses Are Observed. The 
Encyclopedia of Biostatistics.   Armitage Pa and Colton T Eds. . ed. by Armitage PA and Colton T. Vol. 1 John 
Wiley and Sons Inc. Chichester, UK, (1998), pp. 358-9. 
44 M. Kanneganti, M. Mino-Kenudson, and E. Mizoguchi, 'Animal Models of Colitis-Associated Carcinogenesis', J 
Biomed Biotechnol, (2011), 342637. 
45 V. Kettmann, D. Kosfalova, S. Jantova, M. Cernakova, and J. Drimal, 'In Vitro Cytotoxicity of Berberine against 
Hela and L1210 Cancer Cell Lines', Pharmazie, 59 (2004), 548-51. 
46 M. M. Kheir, Y. Wang, L. Hua, J. Hu, L. Li, F. Lei, and L. Du, 'Acute Toxicity of Berberine and Its Correlation 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
32 w
ith the Blood Concentration in Mice', Food Chem Toxicol, 48 (2010), 1105-10. 
47 U. Khin Maung, Khin Myo, Wai Nyunt Nyunt, Kyaw Aye, and U. Tin, 'Clinical Trial of Berberine in Acute 
Watery Diarrhoea', Br Med J (Clin Res Ed), 291 (1985), 1601-5. 
48 B. H. Kim, M. Kim, C. H. Yin, J. G. Jee, C. Sandoval, H. Lee, E. A. Bach, D. H. Hahm, and G. H. Baeg, 
'Inhibition of the Signalling Kinase Jak3 Alleviates Inflammation in Monoarthritic Rats', Br J Pharmacol, 164 
(2011), 106-18. 
49 T. O. Kim, J. Park, M. J. Kang, S. H. Lee, S. R. Jee, D. Y. Ryu, K. Yang, and J. M. Yi, 'DNA Hypermethylation 
of a Selective Gene Panel as a Risk Marker for Colon Cancer in Patients with Ulcerative Colitis', Int J Mol Med, 
31 (2013), 1255-61. 
50 W. H. Ko, X. Q. Yao, C. W. Lau, W. I. Law, Z. Y. Chen, W. Kwok, K. Ho, and Y. Huang, 'Vasorelaxant and 
Antiproliferative Effects of Berberine', Eur J Pharmacol, 399 (2000), 187-96. 
51 W. Kong, J. Wei, P. Abidi, M. Lin, S. Inaba, C. Li, Y. Wang, Z. Wang, S. Si, H. Pan, S. Wang, J. Wu, Y. Wang, 
Z. Li, J. Liu, and J. D. Jiang, 'Berberine Is a Novel Cholesterol-Lowering Drug Working through a Unique 
Mechanism Distinct from Statins', Nat Med, 10 (2004), 1344-51. 
52 M. Kubo, H. Matsuda, K. Tokuoka, S. Ma, and H. Shiomoto, 'Anti-Inflammatory Activities of Methanolic Extract 
and Alkaloidal Components from Corydalis Tuber', Biol Pharm Bull, 17 (1994), 262-5. 
53 C.-L. Kuo, C.-W. Chi, and T.-Y. Liu, 'The Anti-Inflammatory Potential of Berberine {in Vitro} and {in Vivo}', 
Cancer Lett., 203 (2004), 127-37. 
54 C. L. Kuo, C. W. Chi, and T. Y. Liu, 'The Anti-Inflammatory Potential of Berberine in Vitro and in Vivo', Cancer 
Lett, 203 (2004), 127-37. 
55 S. C. Lahiri, and N. K. Dutta, 'Berberine and Chloramphenicol in the Treatment of Cholera and Severe Diarrhoea', 
J Indian Med Assoc, 48 (1967), 1-11. 
56 
C. W. Lau, X. Q. Yao, Z. Y. Chen, W. H. Ko, and Y. Huang, 'Cardiovascular Actions of Berberine', Cardiovasc 
Drug Rev, 19 (2001), 234-44. 
57 I. A. Lee, Y. J. Hyun, and D. H. Kim, 'Berberine Ameliorates Tnbs-Induced Colitis by Inhibiting Lipid 
Per
oxidation, Enterobacterial Growth and Nf-Kappab Activation', Eur J Pharmacol, 648 (2010), 162-70. 
58 G. H. Li, D. L. Wang, Y. D. Hu, P. Pu, D. Z. Li, W. D. Wang, B. Zhu, P. Hao, J. Wang, X. Q. Xu, J. Q. Wan, Y. 
B. Zhou, and Z. T. Chen, 'Berberine Inhibits Acute Radiation Intestinal Syndrome in Human with Abdomen 
Radiotherapy', Med Oncol, 27 (2010), 919-25. 
59 G. R. Lichtenstein, 'Current Research in Crohn's Disease and Ulcerative Colitis: Highlights from the 2010 Acg 
Meeting', Gastroenterol Hepatol (N Y), 6 (2010), 3-14. 
60 H. L. Lin, T. Y. Liu, C. W. Wu, and C. W. Chi, 'Berberine Modulates Expression of Mdr1 Gene Product and the 
Responses of Digestive Track Cancer Cells to Paclitaxel', Br J Cancer, 81 (1999), 416-22. 
61 No authors listed, 'Berberine', Altern Med Rev, 5 (2000), 175-7. 
62 M. Lukas, 'Inflammatory Bowel Disease as a Risk Factor for Colorectal Cancer', Dig Dis, 28 (2010), 619-24. 
63 Amosy E. M'Koma, 'Inflammatory Bowel Disease: An Expanding Global Health Problem', Clinical Medicine 
Insights: Gastroenterology, 6 (2013), 33-47. 
64 E. K. Marinova, D. B. Nikolova, D. N. Popova, G. B. Gallacher, and N. D. Ivanovska, 'Suppression of 
Experimental Autoimmune Tubulointerstitial Nephritis in Balb/C Mice by Berberine', Immunopharmacology, 48 
(2000), 9-16. 
65 S. Melgar, L. Karlsson, E. Rehnstrom, A. Karlsson, H. Utkovic, L. Jansson, and E. Michaelsson, 'Validation of 
Murine Dextran Sulfate Sodium-Induced Colitis Using Four Therapeutic Agents for Human Inflammatory Bowel 
Disease', Int Immunopharmacol, 8 (2008), 836-44. 
66 S. Meng, L.-S. Wang, Z.-Q. Huang, Q. Zhou, Y.-G. Sun, J.-T. Cao, Y.-G. Li, and C.-Q. Wang, 'Berberine 
Ameliorates Inflammation in Patients with Acute Coronary Syndrome Following Percutaneous Coronary 
Intervention', Clin. Exp. Pharmacol. Physiol., 39 (2012), 406-11. 
67 N. A. Molodecky, I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris, G. Chernoff, E. I. Benchimol, R. Panaccione, S. 
Ghosh, H. W. Barkema, and G. G. Kaplan, 'Increasing Incidence and Prevalence of the Inflammatory Bowel 
Diseases with Time, Based on Systematic Review', Gastroenterology, 142 (2012), 46-54 e42; quiz e30. 
68 M. Neurath, I. Fuss, and W. Strober, 'Tnbs-Colitis', Int Rev Immunol, 19 (2000), 51-62. 
69 M. K. Pandey, B. Sung, A. B. Kunnumakkara, G. Sethi, M. M. Chaturvedi, and B. B. Aggarwal, 'Berberine 
Modifies Cysteine 179 of Ikappabalpha Kinase, Suppresses Nuclear Factor-Kappab-Regulated Antiapoptotic 
Gene Products, and Potentiates Apoptosis', Cancer Res, 68 (2008), 5370-9. 
70 
G. H. Rabbani, 'Mechanism and Treatment of Diarrhoea Due to Vibrio Cholerae and Escherichia Coli: Roles of 
Drugs and Prostaglandins', Dan Med Bull, 43 (1996), 173-85. 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
33 71 
G. H. Rabbani, T. Butler, J. Knight, S. C. Sanyal, and K. Alam, 'Randomized Controlled Trial of Berberine 
Sulfate Therapy for Diarrhea Due to Enterotoxigenic Escherichia Coli and Vibrio Cholerae', J Infect Dis, 155 
(1987), 979-84. 
72 L. Rosenberg, K. S. Nanda, T. Zenlea, A. Gifford, G. O. Lawlor, K. R. Falchuk, J. L. Wolf, A. S. Cheifetz, J. D. 
Goldsmith, and A. C. Moss, 'Histologic Markers of Inflammation in Patients with Ulcerative Colitis in Clinical 
Remission', Clin Gastroenterol Hepatol, 11 (2013), 991-6. 
73 K. Saika, and T. Sobue, '[Cancer Statistics in the World]', Gan To Kagaku Ryoho, 40 (2013), 2475-80. 
74 
K. W. Schroeder, W. J. Tremaine, and D. M. Ilstrup, 'Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to 
Moderately Active Ulcerative Colitis. A Randomized Study', N Engl J Med, 317 (1987), 1625-9. 
75 Z. X. Shen, G. Q. Chen, J. H. Ni, X. S. Li, S. M. Xiong, Q. Y. Qiu, J. Zhu, W. Tang, G. L. Sun, K. Q. Yang, Y. 
Chen, L. Zhou, Z. W. Fang, Y. T. Wang, J. Ma, P. Zhang, T. D. Zhang, S. J. Chen, Z. Chen, and Z. Y. Wang, 'Use 
of Arsenic Trioxide (As2o3) in the Treatment of Acute Promyelocytic Leukemia (Apl): Ii. Clinical Efficacy and 
Pharmacokinetics in Relapsed Patients', Blood, 89 (1997), 3354-60. 
76 W. D. Sheng, M. S. Jiddawi, X. Q. Hong, and S. M. Abdulla, 'Treatment of Chloroquine-Resistant Malaria Using 
Pyrimethamine in Combination with Berberine, Tetracycline or Cotrimoxazole', East Afr Med J, 74 (1997), 283-
4. 
77 R. Siegel, D. Naishadham, and A. Jemal, 'Cancer Statistics, 2013', CA Cancer J Clin, 63 (2013), 11-30. 
78 Y. Sun, K. Xun, Y. Wang, and X. Chen, 'A Systematic Review of the Anticancer Properties of Berberine, a 
Natural Product from Chinese Herbs', Anticancer Drugs, 20 (2009), 757-69. 
79 J. Tang, Y. Feng, S. Tsao, N. Wang, R. Curtain, and Y. Wang, 'Berberine and Coptidis Rhizoma as Novel 
Antineoplastic Agents: A Review of Traditional Use and Biomedical Investigations', J Ethnopharmacol, 126 
(2009), 5-17. 
80 C. E. Taylor, and W. B. Greenough, 3rd, 'Control of Diarrheal Diseases', Annu Rev Public Health, 10 (1989), 
221-44. 
81 C. J. Thirupurasundari, R. Padmini, and S. N. Devaraj, 'Effect of Berberine on the Antioxidant Status, 
Ultrastructural Modifications and Protein Bound Carbohydrates in Azoxymethane-Induced Colon Cancer in Rats', 
Chem Biol Interact, 177 (2009), 190-5. 
82 J. K. Triantafillidis, G. Nasioulas, and P. A. Kosmidis, 'Colorectal Cancer and Inflammatory Bowel Disease: 
Epidemiology, Risk Factors, Mechanisms of Carcinogenesis and Prevention Strategies', Anticancer Res, 29 
(2009), 2727-37. 
83 S. Viennot, A. Deleporte, D. Moussata, S. Nancey, B. Flourie, and J. M. Reimund, 'Colon Cancer in Inflammatory 
Bowel Disease: Recent Trends, Questions and Answers', Gastroenterol Clin Biol, 33 Suppl 3 (2009), S190-201. 
84 P. R. Vuddanda, S. Chakraborty, and S. Singh, 'Berberine: A Potential Phytochemical with Multispectrum 
Therapeutic Activities', Expert Opin Investig Drugs, 19 (2010), 1297-307. 
85 Y. M. Wan, Y. Q. Zhu, B. Xia, and J. Luo, 'Treating Tnbs-Induced Colitis in Rats with Probiotics', Turk J 
Gastroenterol, 22 (2011), 486-93. 
86 Y. F. Wang, H. Zhang, and Q. Ouyang, 'Clinical Manifestations of Inflammatory Bowel Disease: East and West 
Differences', J Dig Dis, 8 (2007), 121-7. 
87 W. Wei, H. Zhao, A. Wang, M. Sui, K. Liang, H. Deng, Y. Ma, Y. Zhang, H. Zhang, and Y. Guan, 'A Clinical 
Study on the Short-Term Effect of Berberine in Comparison to Metformin on the Metabolic Characteristics of 
Women with Polycystic Ovary Syndrome', Eur J Endocrinol, 166 (2012), 99-105. 
88 W. Wei, H. Zhao, A. Wang, M.Sui, K. Liang, H. Deng, Y. Ma, Y. Zhang, H. Zhang, Y. Guan, 'A Clinical Study 
on the Short-Term Effect of Berberine in Comparison to Metformin on the Metabolic Characteristics of Women 
with Polycystic Ovary Syndrome', Eur. J. Endocrinol., 166 (2012), 99-105. 
89 S. Wirtz, C. Neufert, B. Weigmann, and M. F. Neurath, 'Chemically Induced Mouse Models of Intestinal 
Inflammation', Nat Protoc, 2 (2007), 541-6. 
90 
S. Wirtz, and M. F. Neurath, 'Mouse Models of Inflammatory Bowel Disease', Adv Drug Deliv Rev, 59 (2007), 
1073-83. 
91 H. L. Wu, C. Y. Hsu, W. H. Liu, and B. Y. Yung, 'Berberine-Induced Apoptosis of Human Leukemia Hl-60 Cells 
Is Associated with Down-Regulation of Nucleophosmin/B23 and Telomerase Activity', Int J Cancer, 81 (1999), 
923-9. 
92 K. Wu, J. Yang, and Q. Zhou, '[Preventive Effects of Berberine on Experimental Colon Cancer and Relationship 
with Cyclooxygenase-2 Expression]', Zhongguo Zhong Yao Za Zhi, 35 (2010), 2768-73. 
93 L. N. Xu, B. N. Lu, M. M. Hu, Y. W. Xu, X. Han, Y. Qi, and J. Y. Peng, 'Mechanisms Involved in the Cytotoxic 
Effects of Berberine on Human Colon Cancer Hct-8 Cells', Biocell, 36 (2012), 113-20. 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
34 94 
F. Yan, L. Wang, Y. Shi, H. Cao, L. Liu, M. K. Washington, R. Chaturvedi, D. A. Israel, H. Cao, B. Wang, R. M. 
Peek, Jr., K. T. Wilson, and D. B. Polk, 'Berberine Promotes Recovery of Colitis and Inhibits Inflammatory 
Responses in Colonic Macrophages and Epithelial Cells in Dss-Treated Mice', Am J Physiol Gastrointest Liver 
Physiol, 302 (2012), G504-14. 
95 L. Ye, Q. Cao, and J. Cheng, 'Review of Inflammatory Bowel Disease in China', ScientificWorldJournal, 2013 
(2013), 296470. 
96 E. Yesilada, and E. Kupeli, 'Berberis Crataegina Dc. Root Exhibits Potent Anti-Inflammatory, Analgesic and 
Febrifuge Effects in Mice and Rats', J Ethnopharmacol, 79 (2002), 237-48. 
97 J. Yin, H. Xing, and J. Ye, 'Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus', Metabolism, 57 
(2008), 712-7. 
98 Zhang H Yu CH, Pan JF, Hong YC, Ren JY, Zhu DY, and Xu XR, 'Determination and Preliminary Studies of 
Metabolism of Berberine in Human Urine after Oral Administration', Chin J Clin Pharmacol 16 (2000), 36-39. 
99 M. F. Zhang, and Y. Q. Shen, '[Antidiarrheal and Anti-Inflammatory Effects of Berberine]', Zhongguo Yao Li 
Xue Bao, 10 (1989), 174-6. 
100 Y. Zhang, X. Li, D. Zou, W. Liu, J. Yang, N. Zhu, L. Huo, M. Wang, J. Hong, P. Wu, G. Ren, and G. Ning, 
'Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine', J Clin Endocrinol 
Metab, 93 (2008), 2559-65. 
101 Y. Zhang, X. Wang, S. Sha, S. Liang, L. Zhao, L. Liu, N. Chai, H. Wang, and K. Wu, 'Berberine Increases the 
Expression of Nhe3 and Aqp4 in Sennosidea-Induced Diarrhoea Model', Fitoterapia, 83 (2012), 1014-22. 
102 
J. J. Zheng, 'Clinical Aspects of Ulcerative Colitis in Mainland China', Chin J Dig Dis, 7 (2006), 71-5. 
103 H. Zhou, and S. Mineshita, 'The Effect of Berberine Chloride on Experimental Colitis in Rats in Vivo and in 
Vitro', J Pharmacol Exp Ther, 294 (2000), 822-9. 
104 B. Zhu, and F. A. Ahrens, 'Effect of Berberine on Intestinal Secretion Mediated by Escherichia Coli Heat-Stable 
Enterotoxin in Jejunum of Pigs', Am J Vet Res, 43 (1982), 1594-8. 
105 D. J. Newman, G. M. Cragg, 'Natural Products as Sources of New Drugs over the 30 Years from 1981 to 2010', J 
Nat Prod, 75 (2012), 311-335. 
 
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
35 INF
ORMED CONSENT 
Northwestern University  (NU)  
The Robert H. Lurie Comprehensive Cancer Center  
Xijing Hospital of the Fourth Military Medical University (FMMU)  
CONSENT FORM FOR RESEARCH  
  
Study Title for Study Participants:  Testing Berberine for the Prevention of Colorectal Cancer 
in Patients with Ulcerati ve Colitis  
 
Official Study Title  for Internet Search on http://www.ClinicalTrials.gov : NWU2014 -03-01, 
Phase I Trial of Berberine in Subjects with Ulcerative Colitis  
 
Principal Investigator:  Kaichun Wu, MD, PhD  
 
Supported by:  National Cancer Institute  (NCI) , Division of Cancer Prevention  (DCP)  
 
 
Introduction 
You are being asked to take part in a research study. This document has important information about the reason 
for the study, what you will do if you choose to be in this research study, and the way we (i.e., Northwestern 
University (NU) in the United States of America, National Cancer Institute (NCI) Division of Cancer 
Prevention (DCP) in the United States of America, and Xijing Hospital) would like to use information about 
y
ou and your health. 
 
Dr. Wu, who is the person responsible for this research study, is interested in both your clinical care and the 
c
onduct of this research study. You may choose to seek the opinion of another doctor or someone not related to 
this research study before taking part in this research study. More importantly, you are not under any obligation 
to participate in any clinical research study offered by your doctor. 
 
This is a clinical trial, a type of research study.  Your study doctor will explain the clinical trial to you.  Clinical 
tria
ls include only people who choose to take part in the research. Please take your time to make your decision 
about volunteering.  You may discuss your decision with your friends and family. You can also discuss this 
study with your health care team.  If you have any questions, you can ask your study doctor for more of an 
explanation. You should only agree to participate in this study if you are comfortable enough with the 
information so that you can make an informed decision about joining. 
 
What is the usual approach to my high risk condition for colorectal cancer? 
You are being asked to take part in this study because you have ulcerative colitis and are at increased risk for 
colorectal cancer. The usual approach for someone at high risk for colorectal cancer includes periodic 
colonoscopies to see if there are any signs of colon cancer.  People who are at increased risk and choose not to 
participate in a study are usually followed closely by their doctor to watch for the development of cancer.  
People who do participate in the study will also be followed closely by their doctor. 
 
What are my other choices if I do not take part in this study?  
If you decide not to take part in this study, you have other choices. For example: 
 you may choose to have the usual approach described above, 
 you may choose to take part in a different study, if one is available,  
 or you may choose to do nothing. 
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
36 Why is this study being done?  
The purpose of this study is to test the safety of Berberine to find out what effects, if any, it has on people with 
ulce
rative colitis in remission and their risk of colorectal  cancer. We will test the effect Berberine has on 
infla
mmation (swelling) of the colon, and how much Berberine is found in your blood after taking it. Berberine 
is a pla
nt-based substance that has been used in China as a medication you can get without a prescription from 
y
our physician (over-the-counter) for treatment for diarrhea. There will be 16-18 people taking part in this 
stud
y.  
 
What are the study groups? 
This study has two study groups. Group 1 will receive the study drug Berberine and Group 2 will receive a 
placebo, a pill that looks like the study drug but contains no medication.  
 
A computer will randomly put you in a study group—like a coin toss— to decide what group you get placed 
int
o. This is done because no one knows if one study group is better, the same, or worse than the other group.  
 
The randomization assignment is 3:1 meaning that: 
 The  chances of receiving the study drug, Berberine, are 75%. 
 The  chances of receiving the placebo are 25% 
 
For every group of 4 people to join the study, 3 people will receive the study drug Berberine and one person 
will receive a placebo. 
 
Once you are put in a group, you cannot switch to the other group. Neither you nor your doctor will know if you 
are receiving the study drug or placebo. Your doctor cannot choose which group you will be in.  
 
 
 
 
 
 
 
 
 
 
 
 
 
How long will I be in this study? 
You will receive the study drugs for 3 months. Even if you do not finish the study, your doctor will continue to 
watch you for side effects and follow your condition for 30 days after you stopped taking the study medication, 
or until all side effects have been resolved, whichever happens later. 
  
What extra tests and procedures will I have if I take part in this study? 
Most of the exams, tests, and procedures you will have are part of the usual approach for your condition. 
However, there are some extra exams and tests that you will need to have if you take part in this study. 
 
Before you begin the study: 
 
Screening is a period during which tests and exams will be done to determine if you are eligible for You agree to 
take part in 
the study  Randomize  (3:1)  
(The computer will 
randomly put you in a 
study group)   
Group 1  
Study Drug, Berberine  
 
Group 2  
Placebo  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
37 pa
rticipation in the study.  Some of the tests and exams may have been recently done by one of your doctors and 
might not need to be repeated. These tests and exams may be done on one day or two days. Most of these are 
pa
rt of regular care for conditions for your ulcerative colitis and would be done even if you do not join the 
stud
y.  Some blood tests will be done for research purposes only and will not change the way your disease is 
treated.  Your study doctor will discuss this with you.  You must sign the informed consent document before 
any screening tests or exams are done only for this study.  Please do not take any medications that have not been 
pre
scribed by your physician (over the counter) in the 3 days prior to your screening.   During this study, please 
do not t
ake any berberine other than what is given to you for purposes of this study.   
 
The following
 tests will be required to determine your eligibility before study treatment can begin: 
 
 R eview of your medical history (including a review of any medications you have taken in the past 3 
months). 
 
 P hysical exam and Vital Signs Assessment (such as height, weight, heart rate, blood pressure, and 
temperature).   
 
 Q uestionnaire about your bowel movements. 
 
 Blood pregnancy test (for women who are able to have children).  About ¾ of a teaspoon (3 - 4 milliliters) 
of blood will be collected for this test. 
 
 B lood tests.  About 2.5 -3.5 teaspoons (12-18 milliliters) of blood will be collected for routine blood tests 
to 
determine your eligibility and to follow your safety, and an extra 2 teaspoons (9-10 milliliters) of blood 
for research. The total blood drawn will be 4.5-5.5  teaspoons (22 -28 milliliters) . 
 
 The most common risks related to drawing blood from your arm are brief pain and possibly a bruise. 
 
 
If the exams and tests show that you can take part in the study, and you choose to, then you will need the following 
extra procedures. 
  
 R ectal biopsies (7 small pieces of colon or rectal  tissue removed by surgery (biopsies) will be taken for 
the study before you begin study drug). This sample is required in order for you to take part in this study 
because the research on the sample is an important part of the study.  This sample will be compared to the 
sa
mple taken at the end of the study, to evaluate the effect of the drug.   
 
 The  research biopsy is done in a similar way to biopsies done for diagnosis.  This will be obtained 
during a standard colonoscopy procedure, which is a test that allows your doctor to look at the inner 
lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a 
colonoscope to look at the colon. A colonoscopy helps find ulcers, colon polyps (abnormal tissue 
growths), tumors, and areas of inflammation or bleeding.  Doctors will use this tissue to look for active 
signs of ulcerative colitis. 
 
 C ommon side effects of a biopsy are bloating, diarrhea, a small amount of bleeding at the time of the 
procedure, pain or discomfort at the biopsy site (which can be treated with regular pain medications), 
and bruising.  Rarely, infection or a small hole might be made in the side of the rectum or colon that 
would require abdominal surgery. 
 
 You will sign a separate consent form before the biopsy is taken. This will be a standard surgical 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
38 c
onsent form from the institution where the biopsy procedure takes place. 
 
Following your colonoscopy, your study visit for screening will last approximately 60 to 90 minutes. Once you 
a
re enrolled in the study, you will receive instructions on when to take the drug and will be provided with a drug 
diar
y to document each dose of study medication that you take.  You should mark any missed or skipped doses 
in this diary as well as any side effects that you experience. 
 
You can pick up the study drug within 6 days of your initial visit (when the tests and procedures were done) at 
the c
linic.  If you are unable to return to the clinic to pick up the study medication, the medication will be 
shipped to your home via FEDEX.  Three (3) bottles of pills (120-count each) will be provided to you at this 
ti
me. 
 
During the study: 
 
Day 0 
You w
ill receive a phone call or come to the doctor’s office to review any medications you are currently taking 
and a
ny side effects that you have had since the previous visit. 
 
You will also be given instructions to begin taking the study medication. You will be asked to take 3 pills three 
ti
mes per day (9 pills total each day).  The pills should be taken after a meal with water every 6-8 hours. You 
will
 be asked to take the study medication for 90 days (3 months) and to keep a record of when you took the 
pills in a study diary (which was provided to you at the previous visit). 
 
This phone call or office visit will take approximately 10-20 minutes. 
 
Day 7 (
+/- 3 days) 
You will receive a telephone call to review any medications you are currently taking and any side effects that 
you have had since the previous visit. The study staff will also go over your diary with you and make sure you 
are taking the study medication as directed. You will continue to take the study medication as directed (3 pills, 
3x each day). Participants should take tablets with water within one hour after a meal, every 6-8 hours. Please 
ha
ve your bottles of study medication available during the phone call. 
 
This phone call will take approximately 10 minutes. 
  
Day 30 (
+/- 7 days) 
You w
ill go to the hospital for a clinical visit.  The study staff w ill review any medications you are currently 
taking and any side effects that you have had since the previous visit. The study staff will also review your 
study diary with you and make sure you are taking the study medication as directed by counting how much 
medic
ation you have left. You will continue to take the study medication as directed (3 pills, 3 x each day). 
Participants should take tablets with water within one hour after a meal, every 6-8 hours. You may receive more 
study medication. You will also receive a physical exam.  Please remember to bring your bottles of study 
medic
ation with you to your visit. 
 
This visit will take approximately 30 minutes. 
 
Day 60 (
+/- 7 days) 
You w
ill go to the hospital for a clinical visit.  The study staff will review any medications you are currently 
taking and any side effects that you have had since the previous visit. The study staff will also review your 
study diary with you and make sure you are taking the study medication as directed by counting how much 
medic
ation you have left. You will continue to take the study medication as directed (3 pills, 3 x each day). 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
39 P
articipants should take tablets with water within one hour after a meal, every 6-8 hours. You may receive more 
stud
y medication. You will also receive a physical exam.  Please remember to bring your bottles of study 
medic
ation with you to your visit. 
 
This visit will take approximately 30 minutes. 
 
After the study: 
 
Day 90 (- 7 days) 
You w
ill go to the hospital for a clinical visit.  The study staff will review any medications you are currently 
taking and any side effects that you have had since the previous visit. The study staff will also review your 
study diary with you and make sure you are taking the study medication as directed. You will also be asked to 
fill out a questionnaire about your bowel movements. 
 
You will also receive a physical exam.  Blood will be drawn (about 3-4 teaspoons or 15-20 mililiters ) f or 
laboratory tests and research.  A colonoscopy will be done to collect rectal biopsies (7 sm a ll pieces of tissue) for 
research purposes.  Please remember to bring all used and unused study medication bottles with you. 
 
This visit will take approximately 60-90 minutes. 
 
Post-study Follow- up: 
 
Day 120 (+/- 7 days) 
You will go to the hospital for a clinical visit.  The study staff will review your current health status and any 
medications you have taken since the previous visit.  
 
This final visit will take approximately 30 minutes. 
 
What possible risks can I expect from taking part in this study?  
If you choose to take part in this study, there is a risk that you may:  
 Lose time at work or home and spend more time in the hospital or doctor’s office than usual. 
 
The drug used in this study may affect how different parts of your body work, such as your liver, kidneys, heart, and 
blood. The study doctor will be testing your blood and will let you know if changes occur that may affect your health.  
 
There is also a risk that you could have side effects.  
Here are important points about side effects: 
 The study doctors do not know who will or will not have side effects. 
 Some side effects may go away soon, some may last a long time, or some may never go away.  
 Some side effects may interfere with your ability to have children. 
 Some side effects may be serious and may even result in death.  
 
Here are important points about how you and the study doctor can make side effects less of a problem: 
 Tell the study doctor if you notice or feel anything different so they can see if you are having a side effect. 
 The study doctor may be able to treat some side effects. 
 The study doctor may adjust the study drugs to try to reduce side effects. 
The tables below show the most common side effects that we know about Berberine, some of which may be 
serious. There might be other side effects that we do not yet know about. If important new side effects are 
found, the study doctor will discuss these with you. 
 
Possible Side Effects of Berberine 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
40   
COMMON, SOME MAY BE SERIOUS  
In 100 people receiving, more than 20 may have:  
 Constipation (decreased number of or difficulty making bowel movements)  
 Abdominal pain (belly pain)  
 Rash  
 
POSSIBLE, SOME MAY BE SERIOUS  
The frequency of some individual side effects has not yet been determined:  
 Nausea  
 Vomiting  
 Drug fever  
 Allergic reaction which may cause rash, low blood pressure, wheezing, shortness of breath, 
swelling of the face or throat  
 Drug interactions with another medication that may change how your medications work or 
increase your risk for side effects  
 Increased risk for miscarriage ( loss of an unborn baby from the uterus before it is able to 
survive outside the mother's body)  
 
Reproductive risks:  You should not get pregnant, breastfeed, or father a baby while in this study. Check with 
the stud
y doctor about what types of birth control, or pregnancy prevention, to use while in this study. 
 
Placebo risks:  Those assigned to the placebo group will receive placebo (a pill which does not have any active 
ing
redient) instead of active study medication (which is Berberine) for the duration of the study. The risks of 
receiving placebo are the same as not receiving any treatment for your condition.  Any concerns you have about 
this should be discussed with the study doctor. 
 
What possible benefits can I expect from taking part in this study?   Participating in this study is 
unlikely to help your condition. This study may help us learn things that could help people in the future. The 
results from this study will provide information that will provide information that will help scientists to better 
understand how Berberine and similar drugs work, which would help other patients with ulcerative colitis in the 
future. 
 
Can I stop taking part in this study?   Yes. You can decide to stop at any time. If you decide to stop 
for any reason, it is important to let the study doctor know as soon as possible so you can stop safely. If 
you stop, you can decide whether or not to let the study doctor continue to provide your medica l 
information to the organization running the study. 
 
The study doctor will tell you about any new information or changes in the study that could affect your health or 
your willingness to continue in the study. 
 
The study doctor may take you out of the study: 
 If your health changes.  
 If the study is no longer in your best interest. 
 If new information becomes available. 
 I f you do not follow the study rules. 
 If the study is stopped early for any reason by the sponsor, Institutional Review Board (IRB) or Ethic s 
Committee,  or CFDA. 
 
What are my rights in this study? 
Taking part in this study is your choice. No matter what decision you make, and even if your decision changes, 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
41 ther
e will be no penalty to you. You will not lose medical care or any legal rights. 
 
For questions about your rights while in this study, call Ms. Li Peng of the Xijing Hospital Ethics 
Committee at 86-29-84771794.  
 
What are the costs of taking part in this study?   The study drug (or placebo) will be supplied at no 
charge while you take part in this study. The cost of study-specific biopsies and exams, tests, and any other 
procedures will be paid for by the study and will not be your responsibility. 
 
Some costs associated with your care may be considered standard of care, and will be billed to you or your 
insurance company. You will have to pay for any costs (including deductibles and co-payments) not covered by 
your health insurer. 
 
Before you decide to be in the study, you should check with your health plan or insurance company to find out 
exactly what they will pay for.  
 
You will not be paid for taking part in this study. 
 
What happens if I am injured or hurt because I took part in this study? 
If you feel you have been injured or hurt as a result of taking part in the study, it is important that you 
tell the study doctor immediately. You will get medical treatment if you are injured or hurt as a result of 
taking part in this study.  
 
The study sponsors will not offer to pay for medical treatment for injury. Your insurance company may 
not be willing to pay for study-related injury. If you have no insurance coverage, you would be 
responsible for any costs. Even though you are in a study, you keep all of your legal rights to receive 
payment for injury caused by medical errors. 
 
Who will see my medical information? Your privacy is very important to us and we will make every 
effort to protect it. Your information may be given out if required by law. For example, certain laws require 
doc
tors to report to health boards if they find a disease like tuberculosis. However, we will do our best to make 
sure that any information that is released will not be able to identify you. Some of your health information, 
and/or information about your specimen, from this study will be kept in a central database for research. Your 
name or contact information will not be put in the database. 
 
There are organizations that may inspect your records. These organizations are required to make sure your 
information is kept private. Some of these organizations are: 
 The Institutional Review Board, IRB, is a group of people who review the research with the goal of 
protecting the people who take part in the study. 
 The Food and Drug Administration and the National Cancer Institute in the US, and similar 
organizations if other countries are involved in the study (such as the China Food and Drug 
Admini
stration). 
 The National Cancer Institute will obtain information for this clinical trial under data collection 
authority Title 42 U.S.C. 285.  
 
Where can I get more information?  
You may visit the NCI website at http://cancer.gov/  for more information about studies or general information 
about cancer. You may also call the NCI Cancer Information Service to get the same information at: 1-800-
4-CANCER (1-800-422 -6237).  
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
42 A de
scription of this clinical trial will be available on http://www.ClinicalTrials.gov , as required by U.S. Law. 
This W eb site will not include information that can identify you. At most, the W eb site will include a summary 
of the results. You can search this W eb site at any time. 
 
Who can answer my questions about this study? 
You can talk to the study doctor about any questions or concerns you have about this study or to report side 
effects or injuries. Contact the study doctor, Dr. Li Xu, at 029-84771540. 
 
 
 
This section is about optional studies you can choose to take part in. 
 
Optional Sample Collections for Laboratory Studies and/or Bio-banking for Possible Future Studies 
 
Researchers are trying to learn more about cancer, diabetes, and other health problems. Much of this 
research is done using samples from your biopsies, blood, urine, or other fluids. Through these 
studies, researchers hope to find new ways to prevent, detect, treat, or cure health problems. 
  
S
ome of these studies may be about genes. Genes carry information about features that are found in 
you and in people who are related to you. Researchers are interested in the way that genes affect how 
your body responds to treatment. 
  
I
f you choose to take part, a sample of tissue from your previous biopsy will be collected. The 
researchers ask your permission to store and use your samples and health information for medical 
research. The research that may be done is unknown at this time. Storing samples for future studies is 
called “biobanking”. The Biobank is being run by the Division of Cancer Prevention and supported by 
the National Cancer Institute. 
  
WHAT
 IS INVOLVED? 
1.       If you agree to take part, your sample and some related information may be stored in the Biobank, 
a
long with samples and information from other people who take part. The samples will be kept until 
they are used up. 
2.       Qualified researchers can submit a request to use the materials stored in the Biobank. A research 
c
ommittee at the clinical trials organization, and/or the National Cancer Institute, will review each 
request. There will also be an ethics review to ensure that the request is necessary and proper. 
Researchers will not be given your name or any other information that could directly identify you. 
3.       Neither you nor your study doctor will be notified if/when research is conducted using your samples. 
4.       Some of your genetic and health information may be placed in central databases that may be public, 
a
long with information from many other people. Information that could directly identify you will not 
be included. 
  
WHAT
 ARE THE POSSIBLE RISKS? 
1.       There is a risk that someone could get access to the personal information in your medical records or 
other
 information we have stored about you. 
2.       There is a risk that someone could trace the information in a central database back to you. Even 
without
 your name or other identifiers, your genetic information is unique to you. The researchers 
believe the chance that someone will identify you is very small, but the risk may change in the future 
a
s people come up with new ways of tracing information. 
3.       There are laws against the misuse of genetic information, but they may not give full protection. New 
he
alth information about inherited traits that might affect you or your blood relatives could be found 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
43 during
 a study. The researchers believe the chance these things will happen is very small, but cannot 
promise that they will not occur. 
  
HO
W WILL INFORMATION ABOUT ME BE KEPT PRIVATE?  
Your privacy is very important to the researchers and they will make every effort to protect it. Here are just a 
few of the steps they will take: 
1.       When your sample(s) is sent to the researchers, no information identifying you (such as your name 
or soc
ial security number) will be sent. Samples will be identified by a unique study code only. 
2.       The list that links the unique code to your name will be kept separate from your sample and health 
infor
mation. Any Biobank and NCI staff with access to the list must sign an agreement to keep your 
identity confidential. 
3.       Researchers to whom the NCI sends your sample and information will not know who you are. They 
must
 also sign an agreement that they will not try to find out who you are. 
4.       Information that identifies you will not be given to anyone, unless required by law. 
5.
       If research results are published, your name and other personal information will not be used. 
  
WHAT
 ARE THE POSSIBLE BENEFITS?  
You will not benefit from taking part. Your samples may be helpful to research whether you do or do not have 
cancer.  The researchers, using the samples from you and others, might make discoveries that could help people 
in the future. 
  
AR
E THERE ANY COSTS OR PAYMENTS?  
There are no costs to you or your insurance. You will not be paid for taking part. If any of the research leads to 
new tests, drugs, or other commercial products, you will not share in any profits. 
  
WHAT
 IF I CHANGE MY MIND?  
If you decide you no longer want your samples to be used, you can call the study doctor, Dr. Li Xu, a t 029-
84771540  who will let the researchers know. Then, any sample that remains in the bank will no longer be used. 
S
amples or related information that have already been given to or used by researchers will not be returned. 
  
WHAT IF I HAVE MORE QUESTIONS? 
If you have questions about the use of your samples for research, contact the study doctor, 
Dr. Li Xu, at 029 -84771540.  
  
P
lease circle your answer to show whether or not you would like to take part in each option ( include only 
applicable questions) : 
  
S
AMPLES FOR THE LABORATORY STUDIES:    
I agree to have my specimen collected and I agree that my specimen sample(s) and related information may be 
used for the laboratory study(ies) described above. 
  
                YES                        NO  
  
I agree that my study doctor, or their representative, may contact me or my physician to see if I wish to learn 
about results from this(ese) study(ies). 
  
                YES                        NO  
  
SAMPLES FOR FUTURE RESEARCH STUDIES:  
My samples and related information may be kept in a Biobank for use in future health research. 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
44   
             YES                        NO  
 
I
 agree that my study doctor, or their representative, may contact me or my physician to see if I wish to 
participate in other research in the future. 
  
                YES                        NO  
  
This is the end of the section about optional studies within the consent template. 
 
 
 
My Signature Agreeing to Take Part in the Main Study 
 
I have read this consent form or had it read to me. I have discussed it with the study doctor and my questions have been 
answered. I will be given a signed copy of this form. I agree to take part in the main study.  
 
Participant’s signature ________________________________ 
 
Date of signature_____________________________________ 
 
 
Signature of person(s) conducting the informed consent discussion _______________________________ 
 
Date of signature_____________________________________  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
45 A
PPENDIX A 
Ulcerative Colitis Disease Activity Index (UCDAI)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Each patient serves as his or her own control to establish the degree of abnormality of the stool frequency 
† The daily bleeding score represents the most severe bleeding of the day 
‡ The physician’s global assessment acknowledges the 3 other criteria, as well as the patient’s daily recall of abdominal 
discomfort, general sense of well-being, and other observations such as physical findings and the patient’s performance 
status 
 
.1. Stool Frequency*  Score  
Normal number of stools/day  for this patient  0 
1–2 Stools/day>normal  1 
3–4 Stools/day>normal  2 
>4 Stools/day>normal  3 
2. Rectal Bleeding† Score  
No blood seen  0 
Streaks of blood with stool less than half of the time  1 
Obvious blood with stool most of the time  2 
Blood alone passed  3 
3. Endoscopic Findings  Score  
Normal or inactive disease  0 
Mild disease (erythema, decreased vascular pattern, mild 
friability)  1 
Moderate disease (marked erythema, absent vascular pattern, 
friability, erosions)  2 
Severe disease (spontaneous bleeding, ulceration)  3 
4. Physician’s Global Assessment‡ Score  
Normal  0 
Mild disease  1 
Moderate disease  2 
Severe disease  3 
UCDAI = total score  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
46 APPENDIX B 
Select CYP450 Inducers, Inhibitors, and Substrates 
 
 1A2 2C19  2D6 3A4 
Inducers  ritonavir  
rifampin  
phenytoin  
omeprazole  
phenobarbital  
nicotine  rifampin  
carbamazepine  
ritonavir  
efavirenz  rifampin  
phenytoin  
phenobarbital  
carbamazepine  efavirenz, nevirapine,  
rifampin, phenytoin,  
phenobarbital,  
carbamazepine,  
glucocorticoids, St. John’s  
Wort, ritonavir, etravirine  
Inhibitors  fluoroquinolones  
cimetidine  
ticlopidine  
fluvoxamine  
amiodarone  
atazanavir  cimetidine  
ketoconazole  
omeprazole  
fluoxetine  
lansoprazole  
paroxetine  
etravirine  ritonavir  
paroxetine  
sertraline  
fluoxetine  
cimetidine  
celecoxib  
amiodarone  
quinidine  
methadone  ritonavir, indinavir, 
nelfinavir,  
amprenavir, atazanavir,  
saquinavir, delavirdine,  
fluconazole, 
ketaconazole,  
itraconazole, amiodarone,  
diltiazem, fluvoxamine,  
nefazodone,  fluoxetine,  
clarithromycin, 
erythromycin,  
posaconazole, grapefruit 
juice,  
Seville orange juice  
Substrates  haloperidol  
theophylline  
zileuton  
amitriptyline  
cyclobenzaprine  
olanzapine  nelfinavir  
lansoprazole  
omeprazole  
pantoprazole  
diazepam  
phenytoin  
voriconazole  
etravirine  metoprolol  
carvedilol  
codeine  
dextrometh - 
orphan  
tramadol  
venlafaxine  clarithromycin, 
cyclosporine,  
erythromycin, alprazolam,  
midazolam, triazolam,  
simvastatin, lovastatin,  
atorvastatin, nifedipine,  
nisoldipine, felodipine,  
PIs, nev irapine, efavirenz  
(2B6>3A4), delavirdine,  
sertraline, bepridil,  
propafenone, amiodarone,  
flecainide, irinotecan,  
pimozide, ergotamine,  
etravirine, maraviroc  
*Table provided by http://www.hivguidelines.org/clinical -guidelines/adults/hiv -drug-drug-
interactions/#APPENDIX%20A:%20ROUTES%20OF%20ELIMINATION%20OF%20HAART%20AND%20THE%20EFFECT%20ON%20CYP450  
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
47 APPENDIX C 
Performance Status Criteria 
 
 
ECOG Performance Status Scale  
  
Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity. Fully active, able to 
carry on all pre -disease performance 
without restriction.  100 Normal, no complaints, no evidence of 
disease.  
90 Able to carry on normal activity; minor 
signs or symptoms of disease.  
1 Symptoms, but ambulatory. Restricted in 
physically strenuous activity, but 
ambulatory and able to carry out work of 
a light or sedentary nature ( e.g., light 
housework, office work).  80 Normal activity with effort; some signs 
or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed <50% of the time. Ambulatory and 
capable of all self -care, but unable to 
carry out any work activities. Up and 
about more than 50% of waking hours.  60 Requires occasional assistance, but is 
able to care for most of his/her needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time. Capable of only 
limited self -care, confined to bed or chair 
more than 50% of waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospitalization 
indicated. Death not imminent.  
4 100% bedridden. Completely disabled. 
Cannot carry on any self -care. Totally 
confined to bed or chair.  20 Very sick, hospitalization indicated. 
Death not imminent.  
10 Moribund, fatal processes progressing 
rapidly.  
5 Dead.  0 Dead.  
 
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
48 AP
PENDIX D 
Patient Diary 
 
DAY ___ 
 
DATE: ___/____/____  
MORNING DOSE  
Time ____ :______  
□ Not taken  
MID-DAY DOSE  
Time ____ :______  
□ Not taken  
EVENING DOSE  
Time ____ :______  
□ Not taken  
Please list any new 
symptoms or 
reasons for missed 
doses:  
________________  
________________  
________________  
________________  
________________   
DAY ___  
 
DATE: ___/____/____  
MORNING DOSE  
Time ____ :______  
□ Not taken  
MID-DAY DOSE  
Time ____ :______  
□ Not taken  
EVENING DOSE  
Time ____ :______  
□ Not taken  
Please list any new 
symptoms or 
reasons for missed 
doses:  
________________  
________________  
________________  
________________  
________________   
DAY ___  
 
DATE: ___/____/____  
MORNING DOSE  
Time ____ :______  
□ Not taken  
MID-DAY DOSE  
Time ____ :______  
□ Not taken  
EVENING DOSE  
Time ____ :______  
□ Not taken  
Please list any new 
symptoms or 
reasons for missed 
doses:  
________________  
________________  
________________  
________________  
________________   
DAY ___  
 
DATE: ___/____/____  
MORNING DOSE  
Time ____ :______  
□ Not taken  
MID-DAY DOSE  
Time ____ :______  
□ Not taken  
EVENING DOSE  
Time ____ :______  
□ Not taken  
Please list any new 
symptoms or 
reasons for missed 
doses:  
________________  
________________  
________________  
________________  
________________   
DAY ___  
 
DATE: ___/____/____  
MORNING DOSE  
Time ____ :______  
□ Not taken  
MID-DAY DOSE  
Time ____ :______  
□ Not taken  
EVENING DOSE  
Time ____ :______  
□ Not taken  
Please list any new 
symptoms or 
reasons for missed 
doses:  
________________  
________________  
________________  
________________  
________________   
DAY ___  
 
DATE: ___/____/____  
MORNING DOSE  
Time ____ :______  
□ Not taken  
MID-DAY DOSE  
Time ____ :______  
□ Not taken  
EVENING DOSE  
Time ____ :______  
□ Not taken  
Please list any new 
symptoms or 
reasons for missed 
doses:  
________________  
________________  
________________  
________________  
________________   
DAY ___  
 
DATE: ___/____/____  
MORNING DOSE  
Time ____ :______  
□ Not taken  
MID-DAY DOSE  
Time ____ :______  
□ Not taken  
EVENING DOSE  
Time ____ :______  
□ Not taken  
Please list any new 
symptoms or 
reasons for missed 
doses:  
________________  
________________  
________________  
________________  
________________  
 Participant Name_______________  
 
Participant ID__________________  
 
NWU2014- 03-01 
Ver
sion 5.7 , November 29, 2016 
49 [
Page left blank due to formatting] 